Introduction {#s1}
============

Neural stem cells (NSCs) reside in two regions of the adult mammalian forebrain: the subgranular zone in the dentate gyrus and the subventricular zone in the lateral wall of the lateral ventricle (SVZ). SVZ NSCs persist throughout adult life ([@bib42]; [@bib50]; [@bib27]), giving rise primarily to neurons in the olfactory bulb as well as some astrocytes in the olfactory bulb ([@bib38]; [@bib39]; [@bib15]; [@bib1]; [@bib32]; [@bib33]; [@bib45]; [@bib27]; [@bib9]) and oligodendrocytes in the corpus callosum and cortex ([@bib53]; [@bib43]). In vivo, these NSCs are quiescent ([@bib13]; [@bib58]), resistant to anti-mitotic agents ([@bib52]; [@bib15], [@bib16]; [@bib21]), long-lived ([@bib1]; [@bib27]), and capable of regenerating the SVZ after injury ([@bib15], [@bib16]; [@bib40]).

Clonal colony-forming assays have been widely used to study neural stem/progenitor cells that give rise to neurons, astrocytes, and oligodendrocytes in adherent cultures ([@bib11]) and non-adherent neurosphere cultures ([@bib61]). However, in the adult forebrain it remains uncertain whether these colonies are formed by quiescent neural stem cells (qNSCs) or by mitotically active and shorter-lived multipotent progenitors ([@bib52]; [@bib16]; [@bib60]; [@bib58], [@bib59]). Moreover, reliance upon retrospective colony-formation assays makes it impossible to directly study qNSCs or NICs as they exist in vivo.

Pioneering work by Alvarez-Buylla and colleagues has demonstrated the existence of a lineage of NSCs and transit amplifying cells in the SVZ that gives rise to neuronal progenitors throughout life ([@bib38]; [@bib14], [@bib13]; [@bib47]; [@bib25]). By electron microscopy and immunofluorescence analysis they identified GFAP-expressing type B cells that appear to be the qNSCs. These cells are resistant to anti-mitotic agents such as AraC and appear capable of repopulating the SVZ after AraC treatment ([@bib13], [@bib15], [@bib16]). Type B cells are thought to give rise to *Ascl1*- and *Dlx2*-expressing type C cells, which are mitotically active and ablated by anti-mitotic agents ([@bib52]; [@bib15], [@bib16]; [@bib58]). The type C cells give rise to Dcx- and PSA-NCAM-expressing type A neuronal progenitors. These studies have provided a critical framework for understanding the SVZ neurogenic lineage, though the inability to purify live cells from each stage of this hierarchy has hampered efforts to assess their properties.

The inability to prospectively identify and isolate uncultured stem cells from the central nervous system (CNS) has contributed to uncertainty regarding the relationship between qNSCs and NICs. SVZ NICs have been enriched by flow cytometry based on CD15 expression ([@bib8]) or ROS levels ([@bib34]). Multiple lines of evidence have demonstrated that NSCs express GFAP and that these cells sustainably contribute to neurogenesis in vivo ([@bib14], [@bib13], [@bib15], [@bib16]; [@bib28]; [@bib51]; [@bib18]; [@bib47]; [@bib58]; [@bib4]; [@bib20]). Pastrana et al. identified quiescent GFAP-GFP^+^EGFR^−^ SVZ cells and speculated that these cells include NSCs that give rise to more mitotically active GFAP-GFP^+^EGFR^+^ and GFAP-GFP^-^EGFR^+^ NICs but did not test this by fate-mapping ([@bib58]). In contrast, it has been suggested that nearly all GFAP-GFP^+^CD133^+^ cells are NICs and that these cells are the qNSCs in the SVZ ([@bib4]). Efforts toward prospective identification have therefore generated conflicting results about whether NICs are quiescent or mitotically active in vivo and regarding their relationship to NSCs.

We have identified regulators of CNS stem cell self-renewal based on their ability to regulate SVZ proliferation and neurogenesis in vivo as well as multipotent NIC self-renewal in culture ([@bib49], [@bib50]; [@bib54]; [@bib10]). However, an important question that we have not been able to address directly is whether those genes are necessary for NSC maintenance in vivo. Impaired NIC self-renewal in culture may not reflect reduced NSC self-renewal in vivo ([@bib30]; [@bib22]). For example, the polycomb transcriptional repressor *Bmi-1* is thought to be required for NSC self-renewal ([@bib49]; [@bib7]; [@bib48]; [@bib69]; [@bib6]; [@bib17]). However, these studies were performed in germline knockout mice that generally die within a month after birth ([@bib67]; [@bib29]; [@bib36]; [@bib57]). Thus, it has not been possible to test whether Bmi-1 is autonomously required by NSCs in the adult brain or whether NSCs differ from NICs in their dependence upon Bmi-1.

Here we report the prospective identification of two phenotypically and functionally distinct populations of cells in the SVZ: GEPCOT cells and pre-GEPCOT cells. The pre-GEPCOTs accounted for 6 ± 3% of adult mouse SVZ cells, were highly quiescent, lacked the ability to form neurospheres or adherent colonies in culture, and included type B1 cells based on marker expression, morphology, and position in vivo. These cells contained long-lived qNSCs based on both fate mapping and temozolomide resistance. GEPCOTs were distinguished by lower GFAP and Glast expression and higher EGFR and PlexinB2 expression. These cells accounted for 3.2 ± 0.7% of cells in the adult mouse SVZ, were highly mitotically active, highly enriched for NICs, and included type C cells based on marker expression, morphology, and position in vivo. Based on fate-mapping these cells were short-lived in the SVZ. Our data thus provide methods to prospectively identify and distinguish qNSCs from NICs.

Results {#s2}
=======

Prospective identification of NICs {#s2-1}
----------------------------------

We enzymatically dissociated adult mouse SVZ cells then sorted cells by flow cytometry into non-adherent cultures at clonal density (0.66 cells/µl of culture medium). We always replated neurospheres to adherent secondary cultures to assess differentiation into TuJ1^+^ neurons, GFAP^+^ astrocytes, and O4^+^ oligodendrocytes. On average, 1.8 ± 0.4% of SVZ cells formed neurospheres (\>50 µm diameter) and 75% of those neurospheres underwent multilineage differentiation (1.4 ± 0.3% of SVZ cells).

We systematically screened 383 antibodies against 330 distinct cell surface antigens ([Supplementary file 1A](#SD1-data){ref-type="supplementary-material"}) to identify markers that could enrich NICs ([Figure 1A](#fig1){ref-type="fig"}). We identified 49 markers by flow cytometry that were heterogeneously expressed among dissociated SVZ cells. For each of these markers we sorted SVZ cells that differed in their level of staining into non-adherent cultures and assessed neurosphere formation. We found 17 markers that enriched NICs relative to unfractionated SVZ cells ([Supplementary file 1A](#SD1-data){ref-type="supplementary-material"}). We multiplexed combinations of these markers to optimize enrichment while ensuring that most NICs were retained within the sorted population.10.7554/eLife.02669.003Figure 1.Prospective identification and isolation of neurosphere-initiating cells.(**A**) A screen of antibodies identified cell surface markers of NICs in the adult mouse SVZ. (**B**) Flow cytometric gating strategy to isolate GEPCOT cells (**G**last^mid^**E**gfr^high^**P**lexinB2^high^**C**D24^−/low^**O**4/PSA-NCAM^−low^**T**er119/CD45^−^) that represent 3.2 ± 0.7% of young adult mouse SVZ cells. Plots represent one representative experiment from at least nine independent experiments. For more information on gating see [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}. (**C**) Frequency of all neurospheres (\>50 µm) and multipotent neurospheres formed by unfractionated SVZ cells (DAPI/CD45/Ter119^−^), GEPCOT cells, and remaining live SVZ cells outside of the GEPCOT population (n = 9 independent experiments). (**D**) Frequency of BrdU^+^ SVZ cells or GEPCOT cells after BrdU pulses in vivo (n = 5--11 mice/time point in 2--3 independent experiments). (**E**) GEPCOT cells efficiently formed multipotent neurospheres in vitro and were mitotically active in vivo. Data always represent mean ± SD. Statistical significance was assessed with two-tailed *t* tests, \*\*\*p\<0.001.**DOI:** [http://dx.doi.org/10.7554/eLife.02669.003](10.7554/eLife.02669.003)10.7554/eLife.02669.004Figure 1---figure supplement 1.Isolating GEPCOT cells by flow cytometry.(**A**) Side scatter (SSC) and forward scatter (FSC) were gated to eliminate debris. The parameters of this gate can be set using mouse bone marrow as shown in the first panel such that myeloid cells fall in the center of the plot. FSC threshold was increased to eliminate as much debris as possible without eliminating cells (this can be checked by sorting events onto a microscope slide and then checking by microscopy to determine whether the events include cells or debris). These steps ensure reproducibility across days in spite of extensive debris in SVZ cell preparations. Sucrose density centrifugation (approximately 90% debris reduction) or myelin depletion using paramagnetic myelin-binding microbeads (Miltenyi Biotec, 130-096-733, approximately ∼95--98% debris reduction) greatly reduce debris but also reduce cell yield by ∼50--60%. (**B**) The sixth gate (CD24/Glast) is drawn using the 'live SVZ cells' population as a guide. On a plot of Glast vs CD24, live SVZ cells should have two clearly resolved populations that are either CD24^mid^ or CD24^−/low^. The CD24 gate excludes all the CD24^mid^ cells and retains all the CD24^−/low^ cells. (**C**) Most NICs and multipotent NICs were contained in the GEPCOT population, which was 20-fold enriched for NICs relative to unfractionated SVZ cells. The remaining non-GEPCOT cells were threefold depleted for NICs relative to unfractionated SVZ cells. Data represent mean ± SD from 11 (neurospheres \>50 μm) or 5 (multipotent neurospheres) independent experiments. Significance was assessed using two-tailed *t* tests (\*\*, p\<0.01; \*\*\*, p\<0.001).**DOI:** [http://dx.doi.org/10.7554/eLife.02669.004](10.7554/eLife.02669.004)

We greatly enriched NICs by isolating live (4′,6-diamidino-2-phenylindole (DAPI) negative) SVZ cells that expressed moderate levels of Glast, high levels of Epidermal Growth Factor Receptor (EGFR), high levels of PlexinB2, negative to low levels of CD24, negative to low levels of O4 and PSA-NCAM, and were negative for the hematopoietic markers Ter119 and CD45. We refer to these Glast^mid^EGFR^high^PlexinB2^high^CD24^−/low^O4/PSA-NCAM^−/low^Ter119/CD45^−^ cells as GEPCOT cells ([Figure 1B](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1A,B](#fig1s1){ref-type="fig"}). GEPCOTs accounted for 3.2 ± 0.7% of all SVZ cells ([Figure 1B](#fig1){ref-type="fig"}). On average, 36 ± 6% of GEPCOT cells formed neurospheres (\>50 µm diameter) and 74% of those neurospheres underwent multilineage differentiation ([Figure 1C](#fig1){ref-type="fig"}). Nearly all of the neurospheres (91%) could be passaged (data not shown). On average, each neurosphere gave rise to 53 ± 41 multipotent secondary neurospheres upon dissociation and replating, demonstrating self-renewal potential. Most NICs from the SVZ were contained within this GEPCOT population ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). Given that individual NICs are unlikely to form colonies with 100% efficiency after dissociation and flow cytometry, most GEPCOT cells likely have the potential to form neurospheres.

NICs are highly proliferative and short-lived in vivo {#s2-2}
-----------------------------------------------------

The ability to prospectively identify NICs made it possible to assess their cell cycle distribution in vivo by administering bromodeoxyuridine (BrdU) to mice. After just a 2 hour pulse of BrdU, 35 ± 2% of GEPCOTs were already BrdU^+^ as compared to only 11 ± 4% of unfractionated SVZ cells ([Figure 1D](#fig1){ref-type="fig"}). Longer pulses of BrdU progressively increased the labeling of the GEPCOT cells. After a 24-hr pulse of BrdU, 89 ± 4% of GEPCOTs were BrdU^+^ as compared to 47 ± 9% of unfractionated SVZ cells ([Figure 1D](#fig1){ref-type="fig"}). GEPCOTs are thus highly mitotically active and enriched for dividing cells relative to unfractionated SVZ cells. The observation that nearly all GEPCOTs incorporated BrdU within 24 hr indicates that few, if any, GEPCOTs are quiescent and that NICs are highly proliferative in vivo.

To assess the persistence of NICs in vivo we performed a series of lineage tracing experiments. Guided by previous observations ([@bib16]; [@bib1]; [@bib2]; [@bib31]; [@bib65]; [@bib35]; [@bib68]) we screened candidate CreER^T2^ alleles for the ability to recombine a conditional *Rosa26-loxp-tdTomato* reporter within NICs in vivo after 5 consecutive days of tamoxifen injection ([Figure 2A](#fig2){ref-type="fig"}; 80 mg/kg body mass/day i.p.). We found that *Dlx1*^*CreERT2*^ ([@bib65]), *Ascl1*^*CreERT2*^ ([@bib31]), *Gli1*^*CreERT2*^ ([@bib1]), *Slc1a3-CreER*^*T*^ ([@bib68]), and *Sox2*^*CreERT2*^ ([@bib2]) labeled 11--94% of NICs 2 days after tamoxifen administration ([Figure 2B--F](#fig2){ref-type="fig"}). With each Cre allele and at earch time point, the frequency of tdTomato^+^ GEPCOTs was statistically indistinguishable from the frequency of tdTomato^+^ neurospheres that arose in culture from unfractionated SVZ cells ([Figure 2B--F](#fig2){ref-type="fig"}). This independently confirms that GEPCOT markers reliably identify uncultured cells with the ability to form neurospheres.10.7554/eLife.02669.005Figure 2.Individual NICs persist only transiently within the SVZ in vivo but are constantly replenished by more primitive neural stem cells.(**A**) Mice bearing inducible Cre alleles and the *Rosa26-loxp-tdTomato* conditional reporter were induced with 5 consecutive days of tamoxifen injections (80 mg/kg/day) then chased for 2 to 60 days before analysis of the percentage of labeled SVZ cells or GEPCOT cells in vivo or the percentage of labeled neurospheres (\>50 µm) in culture. (**B**--**F**) Cells marked by recombination of *Dlx1*^*CreERT2*^ (**B**, n = 4--7 mice/time point in four independent experiments), *Ascl1*^*CreERT2*^ (**C**, n = 3 or 4 mice/time point in three independent experiments), *Gli1*^*CreERT2*^ (**D**), *Slc1a3-CreER*^*T*^ (**E**), or *Sox2*^*CreERT2*^ (**F**, n = 3--4 mice/time point in four independent experiments for **D**--**F**). (**G**) A model consistent with the fate mapping data involving a NSC population that gives rise to a transient NIC population. Data represent mean ± SD. Statistical significance was tested among sequential days of analysis (7d was compared to 2d, 28d was compared to 7d, and 60d was compared to 28d) with a one-way ANOVA followed by Tukey\'s post-hoc tests for multiple comparisons, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, n.s. not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.02669.005](10.7554/eLife.02669.005)

To assess the persistence of NICs in vivo we quantified the frequencies of all SVZ cells, GEPCOTs, and neurospheres that were tdTomato^+^ at 2, 7, 28, or 60 days after tamoxifen treatment. In the absence of tamoxifen we detected no tdTomato expression in SVZ cells, GEPCOTs, or cultured neurospheres in *Dlx1*^*CreERT2*^ mice ([Figure 2B](#fig2){ref-type="fig"}). 2 days after tamoxifen treatment, *Dlx1*^*CreERT2*^ labeled 51 ± 6% of SVZ cells, 15 ± 6% of GEPCOTs, and 11 ± 4% of neurospheres ([Figure 2B](#fig2){ref-type="fig"}). 7 days after tamoxifen this significantly (p\<0.001) declined to 8 ± 5% of SVZ cells, 0.7 ± 0.9% of GEPCOTs, and 0.9 ± 1% of neurospheres ([Figure 2B](#fig2){ref-type="fig"}). 28 days after tamoxifen only rare SVZ cells, GEPCOTs, and neurospheres were labeled ([Figure 2B](#fig2){ref-type="fig"}). *Dlx1*^*CreERT2*^-expressing NICs thus persist in vivo for less than 7 days.

*Ascl1*^*CreERT2*^ labeled most GEPCOTs and neurospheres. In the absence of tamoxifen, only 0.02% of SVZ cells, and no GEPCOTs or neurospheres, were tdTomato^+^ ([Figure 2C](#fig2){ref-type="fig"}). 2 days after tamoxifen, *Ascl1*^*CreERT2*^ labeled 34 ± 7% of SVZ cells, 63 ± 8% of GEPCOTs, and 64 ± 6% of neurospheres ([Figure 2C](#fig2){ref-type="fig"}). 7 days after tamoxifen a similar fraction of SVZ cells remained tdTomato^+^ (35 ± 3%) but the fraction of labeled GEPCOTs and neurospheres significantly (p\<0.01) declined to 40 ± 4% and 45 ± 3%, respectively ([Figure 2C](#fig2){ref-type="fig"}). 28 days after tamoxifen only 16 ± 0.9% of SVZ cells, 16 ± 0.6% of GEPCOTs, and 19 ± 1.0% of neurospheres were labeled. This further decreased to 7.5 ± 1.2% of SVZ cells, 12 ± 0.8% of GEPCOTs, and 8 ± 3% of neurospheres at 60 days after tamoxifen ([Figure 2C](#fig2){ref-type="fig"}). This demonstrates that most *Ascl1*^*CreERT2*^-expressing NICs persist in vivo for less than 28 days.

In contrast to cells labeled with *Dlx1*^*CreERT2*^ or *Ascl1*^*CreERT2*^, cells labeled with *Gli1*^*CreERT2*^, *Slc1a3-CreER*^*T*^, or *Sox2*^*CreERT2*^ exhibited a sustained contribution to the pools of SVZ cells, GEPCOTs, and NICs for at least 60 days after tamoxifen administration ([Figure 2D--F](#fig2){ref-type="fig"}). This suggested the existence of a long-lived NSC population in the SVZ that replenishes NICs and is marked by *Gli1*^*CreERT2*^, *Slc1a3-CreER*^*T*^, and *Sox2*^*CreERT2*^ expression ([Figure 2G](#fig2){ref-type="fig"}).

Identification of GFAP-expressing NSCs in vivo {#s2-3}
----------------------------------------------

To test whether there is an earlier stem cell population in the SVZ we sought a CreER^T2^ allele that recombines in long-lived NSCs but not in NICs. Since prior studies have implicated GFAP as a marker of type B cells and NSCs in the adult SVZ ([@bib14], [@bib13], [@bib16]; [@bib47]; [@bib21]; [@bib20]) we performed lineage-tracing experiments with *GFAP-CreER*^*T2*^ ([@bib23]). In the absence of tamoxifen, only 0.02% of SVZ cells, and no GEPCOTs or neurospheres, were tdTomato^+^ ([Figure 3A](#fig3){ref-type="fig"}). 2 days after tamoxifen treatment, *GFAP-CreER*^*T2*^ labeled only 5 ± 0.6% of SVZ cells, 7 ± 2% of GEPCOTs, and 8 ± 0.9% of neurospheres ([Figure 3A](#fig3){ref-type="fig"}). 7 days after tamoxifen this increased significantly (p\<0.05) to 11 ± 4.3% of SVZ cells, 19 ± 5.5% of GEPCOTs, and 18 ± 6.1% of neurospheres ([Figure 3A](#fig3){ref-type="fig"}). By 28 days after tamoxifen this further increased to 26 ± 3.7% of SVZ cells, 32 ± 4.7% of GEPCOTs, and 35 ± 7.2% of neurospheres ([Figure 3A](#fig3){ref-type="fig"}). At 60 days after tamoxifen we observed 23 ± 2.6% of SVZ cells, 34 ± 8.0% of GEPCOTs, and 37 ± 4.2% of neurospheres labeled ([Figure 3A](#fig3){ref-type="fig"}). *GFAP-CreER*^*T2*^-expressing NSCs thus make a sustained and growing contribution to the SVZ, in contrast to NICs labeled by *Dlx1*^*CreERT2*^ or *Ascl1*^*CreERT2*^.10.7554/eLife.02669.006Figure 3.Identification of a pre-GEPCOT population that gives rise to GEPCOT NICs in vivo.(**A**) *GFAP-CreER*^*T2*^; *Rosa26-loxp-tdTomato* mice were induced with tamoxifen for 5 days, chased for 2 to 60 days without tamoxifen, then conditional reporter expression was analyzed in all SVZ cells, GEPCOTs, and cultured neurospheres (n = 3--5 mice/time point in four independent experiments). (**B**--**D**) *GFAP-CreER*^*T2*^; *Rosa26-loxp-tdTomato* mice were analyzed by flow cytometry to quantify reporter expression in SVZ cells without tamoxifen (**B**), at 2 days (**C**) or 28 days (**D**) after tamoxifen treatment. (**B**) Without tamoxifen, virtually no SVZ cells expressed the reporter. For comparison to **C** and **D**, control SVZ cells are shown stained for Glast and EGFR as well as the distribution of the Glast^high^EGFR^−/low^ fraction with respect to PlexinB2 and O4/PSA-NCAM staining. (**C**) 2 days after tamoxifen, the tdTomato^+^ cells labeled by recombination by the *GFAP-CreER*^*T2*^ stem cell marker were Glast^high^Egfr^−/low^PlexinB2^mid^CD24^−/low^O4/PSA-NCAM^−/low^Ter119/Cd45^−^ (CD24 expression is not shown here), which we describe as 'pre-GEPCOT' cells. (**D**) By 28 days after tamoxifen, Glast^mid^Egfr^high^PlexinB2^high^CD24^−/low^O4/PSA-NCAM^−/low^Ter119/CD45^−^ GEPCOT cells were also labeled. (**E**) The gating strategy to identify the GFAP-expressing pre-GEPCOT population that comprises 6 ± 3% of SVZ cells. Statistical significance was tested among sequential days of analysis with a one-way ANOVA followed by Tukey\'s post-hoc tests for multiple comparisons. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, n.s. not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.02669.006](10.7554/eLife.02669.006)

To better characterize the *GFAP-CreER*^*T2*^-expressing SVZ cells we examined the surface markers expressed by tdTomato^+^ cells 2 days after tamoxifen treatment of *GFAP-CreER*^*T2*^; *Rosa26-loxp-tdTomato* mice. By flow cytometry, tdTomato^+^ cells were highly enriched for Glast^high^EGFR^−/low^PlexinB2^mid^CD24^−/low^O4/PSA-NCAM^−/low^Ter119/CD45^−^ (pre-GEPCOT) cells ([Figure 3B--D](#fig3){ref-type="fig"}). These cells differed from GEPCOT cells in that they exhibited higher levels of Glast and lower levels of EGFR and PlexinB2 expression. pre-GEPCOT cells made up only 6 ± 3% of all SVZ cells ([Figure 3E](#fig3){ref-type="fig"}) and yet, based on *GFAP-CreER*^*T2*^ lineage tracing, gave rise to many SVZ cells, GEPCOTs, and NICs within 28 days of tamoxifen treatment ([Figure 3A](#fig3){ref-type="fig"}). The *GFAP-CreER*^*T2*^-expressing pre-GEPCOTs therefore included NSCs with a much greater capacity to contribute to the SVZ than *Ascl1*^*CreERT2*^-expressing NICs.

To confirm this we sorted pre-GEPCOT cells to test whether they stain with an anti-GFAP antibody. GFAP expression was heterogeneous within the pre-GEPCOT population, with 21 ± 7% being GFAP^high^ and 33 ± 2% being GFAP^low^ ([Figure 4A](#fig4){ref-type="fig"}). This suggests that the pre-GEPCOT population is much more highly enriched for NSCs as compared to unfractionated SVZ cells, which contained only 2 ± 1% GFAP^high^ cells and 6 ± 3% GFAP^low^ cells (both p\<0.01 relative to pre-GEPCOT cells; [Figure 4A](#fig4){ref-type="fig"}).10.7554/eLife.02669.007Figure 4.GFAP-expressing pre-GEPCOT cells are quiescent in vivo but make an enduring contribution to the SVZ.(**A**) Antibody staining for GFAP among SVZ cells, GEPCOTs, and pre-GEPCOTs (scale bar = 5 μm) (n = 3 mice from three independent experiments). (**B**) The frequencies of neurospheres \>50 μm, multipotent neurospheres, adherent colonies, and multipotent adherent colonies (4--6 independent experiments each) formed by unfractionated live SVZ cells, GEPCOTs, and pre-GEPCOTs. (**C**) Frequency of BrdU^+^ SVZ cells or pre-GEPCOT cells after BrdU pulses in vivo (n = 5--11 mice/time point in 2--3 independent experiments; note that SVZ data are from [Figure 1D](#fig1){ref-type="fig"} for comparison purposes but were obtained in the same experiments). (**D**--**H**) Conditional reporter expression in pre-GEPCOT cells at varying times after recombination with the indicated Cre alleles. These data are from the same fate-mapping experiments as shown in [Figures 2 and 3](#fig2 fig3){ref-type="fig"}, including the same SVZ data for comparison purposes. Cre alleles that only transiently contributed to the SVZ (*Dlx1*^*CreERT2*^ and *Ascl1*^*CreERT2*^) did not recombine in pre-GEPCOT cells, while Cre alleles that gave enduring contributions to the SVZ (*Gli1*^*CreERT2*^, *Slc1a3-CreER*^*T*^, and *Sox2*^*CreERT2*^) did recombine in pre-GEPCOT cells. (**I**--**J**) The frequencies and numbers of labeled pre-GEPCOT cells, GEPCOT cells, neuroblasts, and other SVZ cells at varying times after recombination by *GFAP-CreER*^*T2*^ (n = 3--5 mice/time point in four independent experiments). (**K**) Markers that distinguish pre-GEPCOT from GEPCOT cells. (**L**--**M**) Whole-mount SVZs were stained with anti-acetylated tubulin (red), anti-β-catenin (blue), and either anti-GFAP (**L**, green) or anti-EGFR (**M**, green) antibodies and pinwheel structures were inspected for the presence of GFAP^high^ pre-GEPCOT cells (open arrow in **L** and **M**) and EGFR^high^ GEPCOT cells (hatched arrow in **M**) by confocal microscopy. Images were taken at the apical surface except the GFAP depth projection which is a composite of 11 images at 2 μm intervals into the tissue. Scale bar = 5 μm. All data represent mean ± SD. Statistical significance of differences between SVZ and pre-GEPCOT cells in **C** was assessed with two-tailed student\'s *t* tests. Statistical significance of differences in **D**--**J** (among time points) was tested with a one-way ANOVA followed by Tukey\'s post-hoc tests for multiple comparisons. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, n.s. not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.02669.007](10.7554/eLife.02669.007)

pre-GEPCOT cells are long-lived qNSCs {#s2-4}
-------------------------------------

Whereas GEPCOTs were highly enriched for multipotent NICs ([Figure 1C](#fig1){ref-type="fig"}), pre-GEPCOTs were unable to form neurospheres. We sorted unfractionated SVZ cells into culture and found that 1.9 ± 0.5% of the cells formed neurospheres and 2.0 ± 0.4% formed adherent colonies ([Figure 4B](#fig4){ref-type="fig"}). Under the same conditions 32 ± 7% of GEPCOTs formed neurospheres and 38 ± 13% formed adherent colonies ([Figure 4B](#fig4){ref-type="fig"}). In contrast, only very rare pre-GEPCOT cells formed neurospheres (1/1663 cells) and only 0.3 ± 0.4% (9/1973 cells) formed adherent colonies ([Figure 4B](#fig4){ref-type="fig"}).

To assess whether pre-GEPCOT cells are quiescent or frequently dividing in vivo, we administered pulses of BrdU. Although 47 ± 9% of SVZ cells and 89 ± 4% of GEPCOT cells ([Figure 1D](#fig1){ref-type="fig"}) incorporated a 24-hr pulse of BrdU in these experiments, only 3 ± 3% of pre-GEPCOT cells incorporated BrdU in the same mice ([Figure 4C](#fig4){ref-type="fig"}). Similarly, 60 ± 6% of SVZ cells and 91 ± 3% of GEPCOT cells ([Figure 1D](#fig1){ref-type="fig"}) incorporated a 2-week pulse of BrdU in these experiments, but only 4 ± 2% of pre-GEPCOT cells incorporated BrdU ([Figure 4C](#fig4){ref-type="fig"}). These data indicate that pre-GEPCOT cells are quiescent in the SVZ.

To assess whether fate-mapping with CreER^T2^ alleles is consistent with the existence of a pre-GEPCOT qNSC population we assessed whether they recombined in pre-GEPCOT cells. *Dlx1*^*CreERT2*^, which labeled 51 ± 6% of all SVZ cells and 15 ± 6% of GEPCOTs at 2 days after tamoxifen treatment ([Figure 2B](#fig2){ref-type="fig"}), did not label any pre-GEPCOT cells at 2, 7, or 28 days after tamoxifen treatment ([Figure 4D](#fig4){ref-type="fig"}). *Ascl1*^*CreERT2*^, which labeled 34 ± 7% of all SVZ cells and 63 ± 8% of GEPCOTs at 2 days after tamoxifen ([Figure 2C](#fig2){ref-type="fig"}), labeled fewer than 1% of pre-GEPCOT cells at 2, 7, 28, and 60 days after tamoxifen ([Figure 4E](#fig4){ref-type="fig"}). Thus, both of the CreER^T2^ alleles that exhibited declining contributions to the SVZ upon fate-mapping labeled GEPCOTs but not pre-GEPCOTs. Neither the *Dlx1*^*CreERT2*^-expressing GEPCOT NICs nor the *Ascl1*^*CreERT2*^-expressing GEPCOT NICs gave rise to significant numbers of pre-GEPCOT qNSCs in vivo, at least under steady-state conditions.

To assess whether pre-GEPCOTs contain qNSCs we tested whether the CreER^T2^ alleles that sustainably contributed to the SVZ over time (*Gli1*^*CreERT2*^, *Slc1a3-CreER*^*T*^, and *Sox2*^*CreERT2*^) labeled pre-GEPCOT cells. *Gli1*^*CreERT2*^, which sustainably labeled 8--19% of all SVZ cells and 26--40% of GEPCOTs for 60 days after tamoxifen treatment ([Figure 2D](#fig2){ref-type="fig"}), also sustainably labeled 7--13% of pre-GEPCOT cells at 2 to 60 days after tamoxifen treatment ([Figure 4F](#fig4){ref-type="fig"}). *Slc1a3-CreER*^*T*^, which sustainably labeled 21--48% of all SVZ cells and 61--72% of GEPCOTs for 60 days after tamoxifen ([Figure 2E](#fig2){ref-type="fig"}), also labeled 31--36% of pre-GEPCOT cells 2 to 60 days after tamoxifen ([Figure 4G](#fig4){ref-type="fig"}). *Sox2*^*CreERT2*^, which sustainably labeled 49--65% of all SVZ cells and 92--97% of GEPCOTs for 60 days after tamoxifen ([Figure 2F](#fig2){ref-type="fig"}), also sustainably labeled 87--93% of pre-GEPCOT cells 2 to 60 days after tamoxifen ([Figure 4H](#fig4){ref-type="fig"}). Thus all of the CreER^T2^ alleles that gave a sustained contribution to NIC and SVZ labeling also labeled pre-GEPCOTs, consistent with the suggestion that pre-GEPCOT cells contain qNSCs. Moreover, every CreER^T2^ allele that labeled pre-GEPCOT cells exhibited sustained labeling of not only pre-GEPCOT cells but also GEPCOTs, NICs, and unfractionated SVZ cells.

We tested whether the *GFAP-CreER*^*T2*^ recombination pattern was consistent with pre-GEPCOT qNSCs giving rise to GEPCOT NICs in vivo. 2 days after tamoxifen administration to *GFAP-CreER*^*T2*^; *Rosa26-loxp-tdTomato* mice, the tdTomato label was present mainly in pre-GEPCOT cells. On average, 29 ± 7% of pre-GEPCOT cells were tdTomato^+^ whereas only 6.7 ± 1.9% of GEPCOT cells, 2.2 ± 0.5% of PSA-NCAM^high^CD24^mid^ neuroblasts ([@bib58]), and 3.0 ± 0.8% of other SVZ cells were labeled ([Figure 4I](#fig4){ref-type="fig"}). These data indicate that *GFAP-CreER*^*T2*^ recombines efficiently in pre-GEPCOTs but not GEPCOT NICs in vivo. 28 days after tamoxifen treatment, the percentage of labeled pre-GEPCOT cells increased to 44 ± 5.8% of cells ([Figure 4I](#fig4){ref-type="fig"}). The percentages of labeled GEPCOTs, neuroblasts, and other SVZ cells also increased significantly (p\<0.01) by 28 days--32 ± 4.7%, 35 ± 6.8%, and 20 ± 2.2%, respectively. At 60 days after tamoxifen, we continued to observe strong labeling in pre-GEPCOTs, GEPCOTs, and neuroblasts ([Figure 4I](#fig4){ref-type="fig"}). Similar trends were apparent when the data were expressed in absolute numbers ([Figure 4J](#fig4){ref-type="fig"}). These data suggest *GFAP-CreER*^*T2*^-expressing pre-GEPCOT cells include qNSCs that give rise to NICs, neuroblasts, and other SVZ cells ([Figure 4K](#fig4){ref-type="fig"}).

We examined the localization of pre-GEPCOT and GEPCOT cells in whole mount stains of the SVZ. pre-GEPCOTs were distinguished by GFAP expression, a marker of type B cells ([@bib13]) and GEPCOTs were distinguished by EGFR expression, a marker of type C cells ([@bib16]). We stained whole-mount SVZs with antibodies against acetylated tubulin and β-catenin to detect 'pinwheel' structures associated with type B1 stem cells in the SVZ ([@bib47]) then also stained with antibodies against GFAP and EGFR. Consistent with prior results ([@bib47]), we observed GFAP^high^ cells at the center of the pinwheel structures with a single primary cilium on the apical surface contacting the ventricle and a long basal process ([Figure 4L](#fig4){ref-type="fig"}). Since many pre-GEPCOTs recombined with *GFAP-CreER*^*T2*^ but virtually no GEPCOTs did ([Figure 4I](#fig4){ref-type="fig"}), these data indicate that many pre-GEPCOT cells have the morphology and position of type B1 cells in the SVZ. In contrast, EGFR^high^ cells had type C cell morphology: round, unciliated, and generally not contacting the ventricle, consistent with [@bib16] ([Figure 4M](#fig4){ref-type="fig"}). Since all GEPCOT cells express high levels of EGFR ([Figure 1B](#fig1){ref-type="fig"}) while pre-GEPCOT cells have low levels of EGFR ([Figure 3D](#fig3){ref-type="fig"}), these data suggest that many GEPCOT cells have the morphology and position of type C cells.

Anti-mitotic agent eliminates GEPCOT NICs but not pre-GEPCOT qNSCs {#s2-5}
------------------------------------------------------------------

Our observation that pre-GEPCOT cells include qNSCs raised the question of whether pre-GEPCOT cells are resistant to anti-mitotic agents. To test this, we treated mice for 3 consecutive days with the CNS-penetrating DNA-alkylating agent temozolomide (TMZ; 100 mg/kg/day i.p.) ([@bib19]) then assessed SVZ proliferation, composition, and neurosphere formation 3 to 90 days later ([Figure 5A](#fig5){ref-type="fig"}). 3 days after TMZ, mice appeared healthy and had lost less than 3% of their body mass as compared to before TMZ treatment (data not shown). 3 days after TMZ treatment we observed a 23% reduction in the total number of cells per SVZ and this reduction remained nearly constant over the next 90 days ([Figure 5B](#fig5){ref-type="fig"}). 3 days after TMZ we observed an 80% reduction in the number of dividing SVZ cells, based on BrdU incorporation ([Figure 5C](#fig5){ref-type="fig"}, p\<0.001). The number of dividing SVZ cells slowly increased over time, recovering to 50% of normal by 90 days after TMZ treatment ([Figure 5C](#fig5){ref-type="fig"}). 3 days after TMZ only 0.7% of the NICs observed in saline-treated control mice remained in TMZ-treated mice ([Figure 5D](#fig5){ref-type="fig"}, p\<0.001). By 16 days after TMZ treatment NICs recovered to 20% of normal levels ([Figure 5D](#fig5){ref-type="fig"}, p\<0.001). The numbers of NICs continued to increase over time, recovering to 55% of normal by 90 days after TMZ ([Figure 5D](#fig5){ref-type="fig"}, p\<0.001). NICs are thus virtually completely eliminated by TMZ but regenerate over time as expected.10.7554/eLife.02669.008Figure 5.Treatment with temozolomide does not affect the frequency of pre-GEPCOT cells but ablates GEPCOT NICs.(**A**--**F**) Mice were injected with TMZ (100 mg/kg/day) for three consecutive days to ablate dividing cells, then allowed to recover for 3 to 90 days before analysis (TMZ 1x). All TMZ 1x data reflect 5--7 mice per time point from seven independent experiments. (**G**--**L**) Alternatively, mice were serially treated with two doses of TMZ 12 days apart then allowed to recover for 3 to 90 days before analysis (TMZ 2x). All TMZ 2x data reflect 4--9 mice per time point from six independent experiments. At each time point after TMZ treatment the panels show the total number of cells isolated per SVZ (**B** and **H**), the number of SVZ cells per section that incorporated a 2 hr pulse of BrdU (**C** and **I**), the number of multipotent neurospheres that arose in culture per SVZ (**D** and **J**), the number of GEPCOTs per SVZ (**E** and **K**), and the number of pre-GEPCOTs per SVZ (**F** and **L**). (**M**--**P**) Mice were injected with tamoxifen (80 mg/kg/day i.p.) for 5 days, then with TMZ (100 mg/kg/day i.p.) for 3 days, then recovered for 3 or 35 days to observe regeneration. The numbers of labeled GEPCOTs were measured after recombination with *Ascl1*^*CreERT2*^ (**N**, 4 mice per condition from two independent experiments), *Slc1a3-CreER*^*T*^ (**O**, 5--6 mice per condition from three independent experiments), or *GFAP-CreER*^*T2*^ (**P**, 4 mice per condition from two independent experiments). All data represent mean ± SD. Statistical significance was tested with a one-way ANOVA followed by Sidak\'s post-hoc test for the indicated comparisons in **B**--**F** and **H**--**L**. Statistical significance in **N**--**P** was assessed with two-tailed student\'s *t* tests. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, n.s. not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.02669.008](10.7554/eLife.02669.008)

Consistent with the effects of TMZ on NICs, TMZ treatment also eliminated nearly all GEPCOT cells. 3 days after TMZ treatment, only 10% of the GEPCOTs observed in saline-treated control mice remained in TMZ treated mice ([Figure 5E](#fig5){ref-type="fig"}, p\<0.001). By 16 days after TMZ treatment, GEPCOTs recovered to 32% of normal levels ([Figure 5E](#fig5){ref-type="fig"}, p\<0.001). GEPCOTs recovered to 55% of normal levels by 90 days after TMZ treatment ([Figure 5E](#fig5){ref-type="fig"}, p\<0.001).

The numbers of pre-GEPCOT cells in the SVZ were not affected by TMZ treatment ([Figure 5F](#fig5){ref-type="fig"}). If pre-GEPCOT qNSCs regenerate NICs after TMZ treatment then serial TMZ treatment might be expected to deplete pre-GEPCOT cells. To test this we administered two rounds of TMZ 12 days apart ([Figure 5G](#fig5){ref-type="fig"}). Under these circumstances, pre-GEPCOT cells were not depleted 3 days after the second round of TMZ treatment but they were depleted by 90 days after the second round of TMZ ([Figure 5L](#fig5){ref-type="fig"}). Consistent with the observation that pre-GEPCOT cells were sensitive to serial TMZ treatment, we detected little recovery of dividing SVZ cells ([Figure 5I](#fig5){ref-type="fig"}), NICs ([Figure 5J](#fig5){ref-type="fig"}), or GEPCOTs ([Figure 5K](#fig5){ref-type="fig"}) after serial TMZ treatment. These data suggest that GEPCOT NICs are replenished after ablation by pre-GEPCOT qNSCs.

To directly test whether GEPCOTs arise from pre-GEPCOT cells during SVZ regeneration we performed lineage tracing using multiple Cre alleles by first labeling cells with tamoxifen and then treating with TMZ ([Figure 5M](#fig5){ref-type="fig"}). After recombination of a conditional reporter with the GEPCOT marker *Ascl1*^*CreERT2*^, the number of unlabeled GEPCOTs per SVZ increased from 120 ± 50 at 3 days after TMZ to 640 ± 210 at 35 days after TMZ (p\<0.01) but *Ascl1*^*CreERT2*^-labeled GEPCOTs did not significantly change ([Figure 5N](#fig5){ref-type="fig"}). The GEPCOTs, NICs, and neuroblasts that regenerated after TMZ treatment thus did not arise from *Ascl1*^*CreERT2*^-labeled GEPCOTs ([Figure 5N](#fig5){ref-type="fig"}). In contrast, after recombination of a conditional reporter with the pre-GEPCOT markers *Slc1a3-CreER*^*T*^ and *GFAP-CreER*^*T2*^ we observed significant (p\<0.05) increases in the frequencies of labeled GEPCOT cells, NICs, and neuroblasts between 3 and 35 days after TMZ treatment ([Figure 5O,P](#fig5){ref-type="fig"}). These results strongly suggest that pre-GEPCOT cells give rise to GEPCOTs, NICs, and neuroblasts during SVZ regeneration.

Bmi-1 is required by pre-GEPCOT qNSCs and GEPCOT NICs in vivo {#s2-6}
-------------------------------------------------------------

pre-GEPCOT qNSCs and GEPCOT NICs expressed similar levels of *Bmi-1* by qRT-PCR ([Figure 6A](#fig6){ref-type="fig"}). To study the molecular mechanisms that regulate the maintenance of pre-GEPCOT qNSCs and GEPCOT NICs in vivo we generated a floxed allele of *Bmi-1* ([Figure 6---figure supplement 1A,B](#fig6s1){ref-type="fig"}) and conditionally deleted *Bmi-1* using *Nestin-Cre* ([@bib66]). This allele of *Nestin-Cre* deletes broadly throughout the neuroepithelium by E10.5 such that there is nearly homogeneous recombination in the postnatal CNS (<http://cre.jax.org/Nes/Nes-CreNano.html>). Consistent with this, *Nestin-Cre; Bmi-1*^*fl/fl*^ mice exhibited a loss of Bmi-1 protein in the cortex and SVZ by western blot ([Figure 6B](#fig6){ref-type="fig"}) and a loss of *Bmi-1* transcripts in SVZ cells, GEPCOT cells, and pre-GEPCOT cells by qRT-PCR ([Figure 6---figure supplement 1G](#fig6s1){ref-type="fig"}).10.7554/eLife.02669.009Figure 6.Reduced neurogenesis, SVZ cell proliferation, GEPCOT frequency, and pre-GEPCOT frequency in *Nestin-Cre; Bmi-1^fl/fl^* adult mice.(**A**) *Bmi-1* transcript levels in GEPCOT and pre-GEPCOT cells, normalized to β-actin and shown relative to SVZ cells (n = 5 mice in two independent experiments). (**B**) Western blot of SVZ cells and cortical (Ctx) cells from adult *Nestin-Cre*; *Bmi-1*^*fl/fl*^ (Δ/Δ, n = 2) mice and *Bmi-1*^fl/fl^ (fl/fl, n = 2) controls. One of two independent blots is shown. Splenocytes (Spl) from wild-type (+/+) and germline *Bmi-1* deficient (−/−) mice are shown as controls. (**C**--**D**) Representative images of the forebrain (**C**) and cerebellum (**D**). (**E**) Cerebellar molecular and granular layer thickness (n = 3--6 mice/genotype with \>8 measurements from two sections/mouse). (**F**) PCR analysis of genomic DNA from SVZ cells, GEPCOT cells, and pre-GEPCOT cells (3 mice/genotype, one of two independent experiments) as compared to controls (tail DNA and water). A faint non-specific band is visible in Δ/Δ GEPCOT cells. (**G**) The number of BrdU^+^ SVZ cells per section after a 2-hr pulse of BrdU (n = 3 mice/genotype/age, \>6 sections per mouse). (**H**) The frequency of newborn olfactory bulb BrdU^+^NeuN^+^ neurons.after BrdU administration for 7 days followed by 4 weeks without BrdU (n = 3--6 mice/genotype/age in two independent experiments). (**I**) The diameter of primary neurospheres (n = 3--4 mice/genotype/age in four independent experiments. N/A: no neurospheres were formed). (**J**) The frequency of SVZ cells that formed multipotent neurospheres (n = 4--7 mice/genotype/age in four independent experiments). (**K**) The number of secondary neurospheres generated upon subcloning of individual neurospheres (n = 6 neurospheres/mouse for 3 WT mice). (**L**--**N**) The frequency of (**L**) pre-GEPCOT cells, (**M**) GEPCOT cells and (**N**) neuroblasts in the SVZ of 4- and 12-month-old mice (n = 13 mice/genotype/age in three independent experiments). (**O**) *Cdkn2a* (*p16*^*Ink4a*^) mRNA expression normalized to β-actin in SVZ, pre-GEPCOT and GEPCOT cells (n = 5 mice/genotype/age). *Cdkn2a* (*p16*^*Ink4a*^) was undetectable in all *Bmi-1*^fl/fl^ samples. In *Nestin-Cre*; *Bmi-1*^fl/fl^ mutants *Cdkn2a* (*p16*^*Ink4a*^) was detected in SVZ cells (5/5 4-month-old; 5/5 12-month-old) and pre-GEPCOT cells (4/5 4-month-old; 5/5 12-month-old) but usually not in GEPCOT cells (2/5 4-month-old; 1/5 12-month-old). Data represent mean ± SD. In **C**--**E** and **G**--**O**, WT is *Bmi-1*^fl/fl^ and Δ/Δ is *Nestin-Cre*; *Bmi-1*^*fl/fl*^ adult mice, and times are ages of mice. Statistical significance was assessed by two-tailed student\'s *t* tests. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.**DOI:** [http://dx.doi.org/10.7554/eLife.02669.009](10.7554/eLife.02669.009)10.7554/eLife.02669.010Figure 6---figure supplement 1.Targeting strategy for engineering a floxed allele of *Bmi-1* for conditional deletion.(**A**) A bacterial artificial chromosome containing the mouse *Bmi-1* gene (RP23-145I3), was modified to insert a loxP-FRT-Neo-FRT cassette 5′ to exon 2 and a loxP site 3′ to exon 3 to generate the targeting vector. These sites were selected to avoid disrupting conserved sequences, which are potential regulatory elements. Correctly targeted ES cells (*Bmi1*^*fl-Neo*^) were generated using W4 ES cells and identified by southern blotting (**B**) using 5′ and 3′ probes. After generating chimeric mice that gave germline transmission, *Bmi1*^*fl-Neo*^ mice were mated with Flp deleter mice ([@bib62]) to remove the *Neo* cassette. The resulting *Bmi-1*^*fl*^ mice were backcrossed for at least 10 generations onto a C57BL background. Cre recombination of this allele deletes the start codon and generates a frameshift mutation. Open boxes indicate non-coding sequences while black boxes indicate coding sequences. Open and black triangles indicate loxP and FRT sites, respectively. (**C** and **D**) Body mass (**C**; n = 4--13 mice/genotype/age) and brain mass (**D**; n = 5--17 mice/genotype/age) of *Nestin-Cre*; *Bmi-1*^*fl/fl*^ mice and *Bmi-1*^*fl/fl*^ controls. (**E**) Representative images from different regions of the brains of *Nestin-Cre*; *Bmi-1*^*fl/fl*^ mice and *Bmi-1*^*fl/fl*^ controls. (**F**) Representative images from the cortex of *Nestin-Cre*; *Bmi-1*^*fl/fl*^ mice and *Bmi-1*^*fl/fl*^ controls stained for GFAP and DAPI (scale bar equals 50 μm). (**G**) Fraction of mice that exhibited detectable *Bmi-1* transcript levels by RT-PCR in SVZ, pre-GEPCOT and GEPCOT cells from 4 month old *Nestin-Cre*; *Bmi-1*^*fl/fl*^ mice and *Bmi-1*^*fl/fl*^ controls (n = 5 mice/genotype). Data represent mean ± SD. Statistical significance was assessed with two-tailed student\'s *t* tests (\*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001).**DOI:** [http://dx.doi.org/10.7554/eLife.02669.010](10.7554/eLife.02669.010)

*Nestin-Cre; Bmi-1*^*fl/fl*^ mice were modestly but significantly smaller than littermate controls ([Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}). Unlike germline *Bmi-1* deficient mice, which generally die within a month after birth ([@bib67]; [@bib36]; [@bib57]; [@bib7]; [@bib48]), we were able to age *Nestin-Cre; Bmi-1*^*fl/fl*^ mice for up to 2 years. These mice did exhibit neurological deficits that worsened during aging, such as ataxia, as was reported in germline *Bmi-1* deficient mice ([@bib67]). However, the survival of *Nestin-Cre; Bmi-1*^*fl/fl*^ mice throughout adulthood made it possible for the first time to test whether Bmi-1 is autonomously required by qNSCs or NICs in the adult brain.

Consistent with the phenotype of germline *Bmi-1* deficient mice ([@bib67]; [@bib7]; [@bib48]), brain morphology appeared relatively normal in *Nestin-Cre; Bmi-1*^*fl/fl*^ mice ([Figure 6C](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1E](#fig6s1){ref-type="fig"}). Brain size was slightly but significantly reduced in *Nestin-Cre; Bmi-1*^*fl/fl*^ mice as compared to littermate controls ([Figure 6---figure supplement 1D](#fig6s1){ref-type="fig"}) but was normal as a proportion of body mass (data not shown). The cerebellums from *Nestin-Cre; Bmi-1*^*fl/fl*^ mice were smaller than in control mice and had significantly thinner molecular layers ([Figure 6D,E](#fig6){ref-type="fig"}). We also observed unusually prominent GFAP staining throughout the cortex of adult *Nestin-Cre; Bmi-1*^*fl/fl*^ mice ([Figure 6---figure supplement 1F](#fig6s1){ref-type="fig"}). Otherwise, the olfactory bulb, hippocampus, and cortex appeared grossly normal ([Figure 6---figure supplement 1E](#fig6s1){ref-type="fig"}), though additional work will be required to carefully assess laminar organization and identity in each brain region. Our data suggest that the smaller cerebellums and prominent GFAP staining reflect a cell-autonomous requirement for Bmi-1 in fetal neural stem/progenitor cells.

We observed complete *Bmi-1* recombination in sorted SVZ cells, GEPCOT cells, and pre-GEPCOT cells isolated from adult *Nestin-Cre; Bmi-1*^*fl/fl*^ mice ([Figure 6F](#fig6){ref-type="fig"}). 12 month-old *Nestin-Cre; Bmi-1*^*fl/fl*^ mice exhibited a significantly reduced number of SVZ cells that incorporated a 2-hr pulse of BrdU ([Figure 6G](#fig6){ref-type="fig"}). We measured the rate of neurogenesis in *Nestin-Cre*; *Bmi-1*^fl/fl^ mice and *Bmi-1*^fl/fl^ controls by administering BrdU for 7 days (beginning at 4 or 14 months of age) followed by a 4-week chase without BrdU. We quantified the frequency of BrdU^+^NeuN^+^ newborn neurons in sections from the olfactory bulb by microscopy. *Bmi-1* deletion had no effect on neurogenesis at 4 months of age, but significantly reduced olfactory bulb neurogenesis in 14-month-old mice ([Figure 6H](#fig6){ref-type="fig"}, p\<0.01).

Neurospheres formed by *Nestin-Cre; Bmi-1*^*fl/fl*^ SVZ cells were significantly smaller than control neurospheres ([Figure 6I](#fig6){ref-type="fig"}), were unable to undergo multilineage differentiation ([Figure 6J](#fig6){ref-type="fig"}), and could not be passaged ([Figure 6K](#fig6){ref-type="fig"}). In contrast, control neurospheres readily underwent multilineage differentiation ([Figure 6J](#fig6){ref-type="fig"}) and were able to generate multipotent daughter neurospheres upon subcloning into secondary cultures ([Figure 6K](#fig6){ref-type="fig"}).

To assess whether *Bmi-1* deficiency affected pre-GEPCOT qNSCs or GEPCOT NICs in vivo we assessed the frequencies of these cells in SVZs from 4 and 12 month old *Nestin-Cre; Bmi-1*^*fl/fl*^ mice and littermate controls. The frequency of pre-GEPCOT cells was significantly reduced at 4 months of age ([Figure 6L](#fig6){ref-type="fig"}). We observed no significant effects on the frequencies of GEPCOT cells ([Figure 6M](#fig6){ref-type="fig"}) or neuroblasts ([Figure 6N](#fig6){ref-type="fig"}) at 4 months of age. However, each of these populations was significantly depleted in 12 month old *Nestin-Cre; Bmi-1*^*fl/fl*^ mice ([Figure 6L--N](#fig6){ref-type="fig"}). Bmi-1 is thus required for the maintenance of normal numbers of pre-GEPCOT qNSCs and GEPCOT NICs in the adult brain. Nonetheless, some pre-GEPCOT cells, GEPCOT cells, and neurogenesis did persist for at least a year in adult mice, demonstrating that NSCs are not absolutely dependent upon Bmi-1 for their maintenance in the adult brain.

Bmi-1 promotes the maintenance of neural stem cells partly by repressing the *Cdkn2a* (*p16*^*Ink4a*^/*p19*^*Arf*^) locus ([@bib29]; [@bib49], [@bib48]; [@bib6]). We were unable to detect *Cdkn2a* (*p16*^*Ink4a*^) transcripts in wild-type SVZ cells, pre-GEPCOT qNSCs, or GEPCOT NICs in 4-month-old (0/5) or 12 month old (0/5) mice ([Figure 6O](#fig6){ref-type="fig"}). In contrast, 4-month old *Bmi-1*-deficient SVZ cells (5/5 mice) and pre-GEPCOT cells (4/5 mice) did express *Cdkn2a* (*p16*^*Ink4a*^) and the level of *Cdkn2a* (*p16*^*Ink4a*^) expression significantly increased between 4 and 12 months of age ([Figure 6O](#fig6){ref-type="fig"}; detected in 5/5 mice for both populations). Low level *Cdkn2a* (*p16*^*Ink4a*^) expression was detected in GEPCOT cells from two of five 4 month-old *Bmi-1*-deficient mice and in GEPCOT cells from one of five 12 month old *Bmi-1*-deficient mice ([Figure 6O](#fig6){ref-type="fig"}). Bmi-1 is thus required to repress *Cdkn2a* (*p16*^*Ink4a*^) expression in pre-GEPCOT qNSCs.

*Bmi-1* promotes adult neurogenesis and gliogenesis in vivo {#s2-7}
-----------------------------------------------------------

To conditionally delete *Bmi-1* in the adult brain we used *Nestin-CreER*^*T2*^, which deletes broadly throughout the SVZ, including within qNSCs that give rise to SVZ cells after AraC treatment ([@bib21]). We observed significantly lower levels of *Nestin* transcripts within pre-GEPCOT qNSCs as compared to GEPCOT NICs ([Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}) and only 9.3 ± 7.3% of pre-GEPCOTs stained positively for Nestin protein as compared to 89.7 ± 8.5% of GEPCOTs and 39.0 ± 5.3% of SVZ cells ([Figure 7---figure supplement 1B](#fig7s1){ref-type="fig"}). We also observed higher levels of *Nestin* transgene expression in GEPCOT cells as compared to pre-GEPCOT cells, including *Nestin-mCherry* and *Nestin-GFP* ([Figure 7---figure supplement 1C,D](#fig7s1){ref-type="fig"}). However, when we analyzed recombination of a conditional reporter in *Nestin-CreER*^*T2*^ mice, we observed labeling of 99 ± 1.1% of GEPCOT cells and 96 ± 1.9% of pre-GEPCOT cells ([Figure 7---figure supplement 1E](#fig7s1){ref-type="fig"}). Therefore, although endogenous *Nestin* is expressed at lower levels in qNSCs as compared to NICs, *Nestin* second intronic enhancer transgenes are variably expressed in both pre-GEPCOT qNSCs and GEPCOT NICs, and *Nestin-CreER*^*T2*^ gives nearly complete recombination in both cell populations.

We administered tamoxifen in the chow of *Nestin-CreER*^*T2*^; *Bmi-1*^fl/fl^ mice and littermate controls for 30 days beginning at 6 weeks of age and assessed recombination efficiency 2 weeks after completing tamoxifen treatment (i.e., starting at 3 months of age). Polymerase chain reaction (PCR) analysis of genomic DNA from individual neurospheres revealed complete deletion of *Bmi-1* in at least 95% of neurospheres ([Figure 7---figure supplement 2A,B](#fig7s2){ref-type="fig"}). Western blot analysis demonstrated a near total loss of Bmi-1 protein from neurospheres ([Figure 7A](#fig7){ref-type="fig"}), consistent with the high rate of recombination in individual neurospheres. By PCR analysis of genomic DNA we observed near complete recombination in unfractionated SVZ cells and complete recombination in pre-GEPCOT and GEPCOT cells isolated from adult *Nestin-CreER*^*T2*^; *Bmi-1*^fl/fl^ mice ([Figure 7B](#fig7){ref-type="fig"}).10.7554/eLife.02669.011Figure 7.Reduced neurogenesis, gliogenesis, SVZ cell proliferation, and GEPCOT NICs in adult *Nestin-CreER^T2^; Bmi-1^fl/fl^* mice relative to littermate controls.(**A**) Western blot of pooled neurospheres (NS) cultured at 2 weeks after tamoxifen treatment (n = 2 mice/genotype). Wild-type and germline *Bmi-1*^−/−^ bone marrow (BM) cells are shown as controls. (**B**) PCR analysis of genomic DNA from SVZ cells, GEPCOT cells, and pre-GEPCOT cells 1 day after tamoxifen treatment as compared to controls (tail DNA and water) (n = 2--3 mice/genotype). A faint non-specific product is visible in lanes 3, 8 and 10. (**C**) The frequency of newborn BrdU^+^NeuN^+^ neurons in the olfactory bulb (n = 5--11 mice/genotype/timepoint in 10 independent experiments). (**D**--**G**) The frequencies of newborn BrdU^+^ Calbindin^+^ (**D**), Calretinin^+^ (**D**), Tyrosine Hydroxylase^+^ (**E**), and S100β^+^ (**F**) cells in the olfactory bulb or GST-pi^+^ (**G**) cells in the cortex (n = 3--5 mice/genotype/timepoint in two independent experiments). For panels **C**--**G** BrdU was administered for 7 days followed by 4 weeks without BrdU. (**H**) The frequency (left panel) or number (right panel) of BrdU^+^ SVZ cells per section after a 2-hr pulse of BrdU (n = 3--11 mice/genotype/timepoint in six independent experiments). (**I**--**J**) The number of Dcx^+^ neuroblasts per section (**I**) or frequency of CD24^mid^PSA-NCAM^+^ neuroblasts as determined by flow cytometry (n = 4--11 mice/genotype/age in 6--7 independent experiments). (**K** and **N**) The frequencies of SVZ cells that formed neurospheres (\>50 µm; **K**), or multipotent neurospheres (N; n = 5--9 mice/genotype/timepoint in six independent experiments). (**L**) The diameter of primary neurospheres from mice 2--4 weeks after tamoxifen treatment (n = 7--9 mice/genotype in two independent experiments). (**M**) Representative primary neurospheres from mice 2 weeks after tamoxifen treatment. (**O**) The number of multipotent secondary neurospheres generated upon subcloning of individual primary neurospheres (n = 3--9 mice/genotype/timepoint in three independent experiments). (**P** and **Q**) The frequency of pre-GEPCOT cells (**P**) or GEPCOT cells (**Q**) in the SVZ (n = 3--11 mice/genotype/timepoint in seven independent experiments). (**R**) qRT-PCR analysis of *Cdkn2a* (*p16*^*Ink4a*^) transcript levels expression normalized to β-actin in SVZ, pre-GEPCOT and GEPCOT cells (n = 5--9 mice/genotype/timepoint). All data represent mean ± SD. In **A** and **C**--**R**, WT is *Bmi-1*^fl/fl^ and Δ/Δ is *Nestin-CreER*^*T2*^; *Bmi-1*^*fl/fl*^ adult mice, and timepoints are times after tamoxifen induction beginning at 6 weeks of age. Statistical significance was assessed with two-tailed student\'s *t* tests. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.**DOI:** [http://dx.doi.org/10.7554/eLife.02669.011](10.7554/eLife.02669.011)10.7554/eLife.02669.012Figure 7---figure supplement 1.*Nestin* expression in GEPCOT and pre-GEPCOT cells.(**A**) *Nestin* transcript expression relative to *β-actin* (n = 5 mice in two independent experiments). (**B**) Frequency of cells within each cell population that stained positively for Nestin protein (n \>50 cells counted/population in each of three independent experiments). (**C** and **D**) Representative histograms of *Nestin-mCherry* (**C**) and *Nestin-GFP* (**D**) transgene expression in SVZ cells, GEPCOT cells, and pre-GEPCOT cells. Shaded histograms represent background fluorescence in wild-type controls (mean ± SD reflects data from three mice per genotype in a single experiment). (**E**) *Nestin*-*CreER*^*T2*^; *Rosa26-loxp-tdTomato* mice were treated with 5 consecutive days of tamoxifen injections (80 mg/kg/day) then chased for 2 days (n = 4 mice). The frequency of tdTomato+ cells in each cell population is shown. Untreated mice reflect the background level of recombination (n = 2 mice). Data represent mean ± SD. Statistical significance was assessed with two-tailed student\'s *t* tests (\*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001).**DOI:** [http://dx.doi.org/10.7554/eLife.02669.012](10.7554/eLife.02669.012)10.7554/eLife.02669.013Figure 7---figure supplement 2.Adult *Nestin-CreER^T2^; Bmi-1^fl/fl^* mice show *Bmi-1* recombination in pre-GEPCOT qNSCs.(**A** and **B**) PCR of genomic DNA from individual neurospheres cultured from *Bmi-1*^fl/fl^ control (**A**) or *Nestin-CreER*^*T2*^; *Bmi-1*^fl/fl^ (**B**) mice 2 weeks after tamoxifen treatment. Tail DNA was used for positive controls and water for negative control. Since *Bmi-1* deficient neurospheres were smaller than control neurospheres, PCR reactions were run for an additional five cycles in **B** as compared to **A** to detect products. In cases where no PCR product was detected (such as lanes 3 and 7) these samples were excluded from calculations of deletion efficiency. In this experiment all *Nestin-CreER*^*T2*^; *Bmi-1*^*fl/fl*^ neurospheres with successful PCR product amplification showed complete excision of the floxed allele. Note that a non-specific product is visible in lane 4. (**C**) Body mass of *Bmi-1*^*fl/fl*^ control (WT) and *Nestin-CreER*^*T2*^; *Bmi-1*^*fl/fl*^ (Δ/Δ) mice 6 months after tamoxifen treatment (n = 5--8 mice/genotype). (**D**) Thickness of the molecular and granular layers of cerebellum from *Bmi-1*^fl/fl^ control and *Nestin-CreER*^*T2*^; *Bmi-1*^*fl/fl*^ mice 10--14 months after tamoxifen treatment (n = 3--4 mice/genotype with \>8 measurements from two sections/mouse). (**E**--**F**) The number of Mcm2^+^ (**E**) and Ki67^+^ (**F**) SVZ cells per section (n = 4--11 mice/genotype/age in seven independent experiments). (**G**) Representative images of SVZ sections from 6- and 12-month old *Bmi-1*^*fl/fl*^ control (WT) and *Nestin-CreER*^*T2*^; *Bmi-1*^*fl/fl*^ (Δ/Δ) mice. (**H**) RT-PCR was performed on pre-GEPCOT cells isolated from wild type (+/+; 3 months old), *Bmi-1*^fl/fl^ (fl/fl), or *Nestin-CreER*^*T2*^; *Bmi-1*^fl/fl^ mice (Δ/Δ) 6 months after tamoxifen treatment to assess *Cdkn2a* (*p16*^*Ink4a*^) transcript levels. Amplification of specific products was observed in 2 of 3 Δ/Δ samples but not in any others. Data represent mean ± SD. Statistical significance was assessed with two-tailed student\'s *t* tests (\*\*p\<0.01, \*\*\*p\<0.001).**DOI:** [http://dx.doi.org/10.7554/eLife.02669.013](10.7554/eLife.02669.013)

Body mass ([Figure 7---figure supplement 2C](#fig7s2){ref-type="fig"}), brain histology (data not shown), and cerebellum size ([Figure 7---figure supplement 2D](#fig7s2){ref-type="fig"}) were all grossly normal in *Nestin-CreER*^*T2*^; *Bmi-1*^fl/fl^ mice six months after tamoxifen treatment. To assess the consequences of *Bmi-1* deletion from adult neural stem/progenitor cells, we measured the rate of neurogenesis in *Nestin-CreER*^*T2*^; *Bmi-1*^fl/fl^ mice and *Bmi-1*^fl/fl^ controls by administering BrdU for 7 days (beginning at 2 weeks, 6 months and 12 months after tamoxifen treatment, at which time the mice were approximately 3 months old, 9 months old and 15 months old, respectively) followed by a 4-week chase without BrdU. *Bmi-1* deficiency had no effect on the frequency of BrdU^+^NeuN^+^ newborn neurons in the olfactory bulb 2 weeks after tamoxifen treatment but significantly reduced neurogenesis 6 and 12 months after tamoxifen ([Figure 7C](#fig7){ref-type="fig"}, p\<0.05). The reduced neurogenesis in *Bmi-1* mutant mice was evident in all subsets of neurons that we investigated, including BrdU^+^Calretinin^+^ neurons, BrdU^+^Calbindin^+^ neurons, and BrdU^+^Tyrosine Hydroxylase^+^ neurons ([Figure 7D,E](#fig7){ref-type="fig"}). *Bmi-1* is therefore required in adult neural stem/progenitor cells for normal neurogenesis but *Bmi-1* deficiency did not completely eliminate the generation of forebrain neurons during the first year of life.

Consistent with prior studies, the vast majority of the newborn cells in the adult olfactory bulb were neurons, but the small numbers of astrocytes that arose in the olfactory bulb and oligodendrocytes that arose in the cortex were also diminished after *Bmi-1* deletion. The frequency of newborn olfactory bulb BrdU^+^S100β^+^ astrocytes appeared normal 6 months after tamoxifen treatment but was significantly reduced 12 months after tamoxifen in *Bmi-1* mutant mice ([Figure 7F](#fig7){ref-type="fig"}). The frequency of newborn cortical BrdU^+^GST-pi^+^ oligodendrocytes declined 6 months after tamoxifen treatment and could no longer be detected after 12 months ([Figure 7G](#fig7){ref-type="fig"}). The deficits in neurogenesis and gliogenesis became worse over time after *Bmi-1* deletion.

We quantified the frequency of SVZ cells that incorporated a 2-hr pulse of BrdU. *Bmi-1* mutant mice had significant reductions in the frequencies of BrdU^+^ SVZ cells at 2 weeks (50% reduction, p\<0.02), 6 months (55% reduction, p\<0.02) and 12 months (90% reduction, p\<0.001) after tamoxifen treatment ([Figure 7H](#fig7){ref-type="fig"}). *Bmi-1* mutant mice also had significant (p\<0.001) reductions in the frequencies of Mcm2^+^ ([Figure 7---figure supplement 2E,G](#fig7s2){ref-type="fig"}) and Ki67^+^ ([Figure 7---figure supplement 2F](#fig7s2){ref-type="fig"}) SVZ cells. Consistent with this, *Bmi-1* mutant mice exhibited significant (p\<0.001) declines in the frequencies of Dcx^+^ ([Figure 7I](#fig7){ref-type="fig"}) and CD24^mid^PSA-NCAM^+^ neuroblasts ([Figure 7J](#fig7){ref-type="fig"}) 6 and 12 months after tamoxifen treatment.

GEPCOT NICs acutely depend upon Bmi-1 in the adult SVZ {#s2-8}
------------------------------------------------------

To assess whether *Bmi-1* is required by adult NICs we plated SVZ cells from tamoxifen-treated *Nestin-CreER*^*T2*^; *Bmi-1*^fl/fl^ and control mice in non-adherent cultures and assessed GEPCOT cell frequency. 2 weeks after tamoxifen treatment the frequencies of NICs ([Figure 7K](#fig7){ref-type="fig"}) and GEPCOTs ([Figure 7Q](#fig7){ref-type="fig"}) were unchanged in *Bmi-1* mutant mice as compared to littermate controls. However, the *Bmi-1*-deficient neurospheres were significantly smaller than control neurospheres ([Figure 7L,M](#fig7){ref-type="fig"}) and did not undergo multilineage differentiation ([Figure 7N](#fig7){ref-type="fig"}; they formed only astrocytes upon transfer to adherent cultures) or self-renew upon subcloning ([Figure 7O](#fig7){ref-type="fig"}). At 6 and 12 months after tamoxifen treatment, *Bmi-1* deficient SVZ cells formed virtually no neurospheres ([Figure 7K](#fig7){ref-type="fig"}). Consistent with this, *Nestin-CreER*^*T2*^; *Bmi-1*^fl/fl^ mice also had significantly lower frequencies of GEPCOTs than control mice at 6 months and 12 months after tamoxifen treatment, and the magnitude of the depletion increased over time ([Figure 7Q](#fig7){ref-type="fig"}). Virtually no GEPCOTs could be found in *Nestin-CreER*^*T2*^; *Bmi-1*^fl/fl^ mice 12 months after tamoxifen treatment ([Figure 7Q](#fig7){ref-type="fig"}). These data demonstrate that GEPCOT NICs require *Bmi-1* in vivo for their maintenance in the adult SVZ, though the cells are able to persist for several months after *Bmi-1* deletion before they are completely eliminated.

To test whether qNSCs depend upon Bmi-1 for their maintenance in vivo we examined the frequency of pre-GEPCOT cells in tamoxifen-treated *Nestin-CreER*^*T2*^; *Bmi-1*^fl/fl^ mice and littermate controls. pre-GEPCOT cells were not depleted at 2 weeks or 6 months after tamoxifen treatment ([Figure 7P](#fig7){ref-type="fig"}). We observed a clear trend toward reduced pre-GEPCOT cell frequency in *Nestin-CreER*^*T2*^; *Bmi-1*^fl/fl^ mice 12 months after tamoxifen treatment but the effect was not statistically significant.

To test whether there was a loss of Bmi-1 function in these cells we performed qRT-PCR to assess *Cdkn2a* (*p16*^*Ink4a*^) expression in cells from *Nestin-CreER*^*T2*^; *Bmi-1*^fl/fl^ mice. One mechanism by which Bmi-1 promotes the maintenance of neural stem/progenitor cells is by negatively regulating *Cdkn2a* (*p16*^*Ink4a*^) expression ([@bib29]; [@bib49]; [@bib7]; [@bib48]). We did not detect *Cdkn2a* (*p16*^*Ink4a*^) transcripts in wild-type SVZ cells, pre-GEPCOT qNSCs, or GEPCOT NICs 2 weeks (0/5), 3 months (0/6), or 8 months (0/7) after tamoxifen treatment ([Figure 7R](#fig7){ref-type="fig"}). We rarely detected *Cdkn2a* (*p16*^*Ink4a*^) transcripts in SVZ cells or GEPCOT cells from *Nestin-CreER*^*T2*^; *Bmi-1*^fl/fl^ mice 2 weeks (0/5 SVZ, 0/5 GEPCOT), 3 months (0/5 SVZ, 1/5 GEPCOT) or 8 months (1/9 SVZ, 0/9 GEPCOT) after tamoxifen treatment. *Cdkn2a* (*p16*^*Ink4a*^) transcripts were rarely detected in pre-GEPCOT cells from *Nestin-CreER*^*T2*^; *Bmi-1*^fl/fl^ mice 2 weeks (0/5) or 3 months (1/5) after tamoxifen treatment. However, 8 months after tamoxifen treatment *Cdkn2a* (*p16*^*Ink4a*^) expression was detected in pre-GEPCOT cells from seven of nine *Nestin-CreER*^*T2*^; *Bmi-1*^fl/fl^ mice ([Figure 7R](#fig7){ref-type="fig"}, [Figure 7---figure supplement 2H](#fig7s2){ref-type="fig"}). These data demonstrate that Bmi-1 is required during adulthood to negatively regulate *Cdkn2a* (*p16*^*Ink4a*^) expression in pre-GEPCOT qNSCs but that these cells are depleted more slowly than GEPCOT NICs in the adult SVZ. Although high levels of *Cdkn2a* (*p16*^*Ink4a*^) expression are associated with cellular senescence, we were unable to detect any increase in senescence associated β-galactosidase activity in pre-GEPCOT cells from 14 month old *Nestin-Cre; Bmi-1*^*fl/fl*^ mice or in cultured neural stem/progenitor cells from *Bmi-1* germline deficient mice (data not shown).

Discussion {#s3}
==========

By screening almost 400 antibodies against distinct cell surface antigens we identified two phenotypically and functionally distinct populations of neural stem/progenitor cells from the adult mouse SVZ ([Figure 8](#fig8){ref-type="fig"}). GEPCOT cells were highly enriched for NICs ([Figure 1C](#fig1){ref-type="fig"}) and highly mitotically active in vivo ([Figure 1D](#fig1){ref-type="fig"}) but persisted only transiently in the SVZ based on fate mapping with *Ascl1*^*CreERT2*^ or *Dlx1*^*CreERT2*^ ([Figure 2B,C](#fig2){ref-type="fig"}). In contrast, pre-GEPCOT cells lacked the ability to form neurospheres or adherent colonies in culture ([Figure 4B](#fig4){ref-type="fig"}), and were quiescent in vivo ([Figure 4C](#fig4){ref-type="fig"}) but were long-lived in the SVZ based on fate mapping with the stem cell markers *Slc1a3-CreER*^*T*^ ([@bib68]), *GFAP-CreER*^*T2*^ ([@bib20]), *Sox2*^*CreERT2*^ ([@bib2]), and *Gli1*^*CreERT2*^ ([@bib1]; [@bib35]) ([Figure 4F--J](#fig4){ref-type="fig"}). In contrast to GEPCOT NICs, pre-GEPCOT cells were resistant to TMZ ([Figure 5E,F](#fig5){ref-type="fig"}). Although TMZ eliminated virtually all NICs from the SVZ ([Figure 5D](#fig5){ref-type="fig"}), the dividing cells, NICs, and GEPCOTs regenerated within a month of TMZ treatment ([Figure 5](#fig5){ref-type="fig"}). The persistence of pre-GEPCOT cells after TMZ ([Figure 5F](#fig5){ref-type="fig"}), and the regeneration of GEPCOTs from a precursor that expresses *Slc1a3-CreER*^*T*^ and *GFAP-CreER*^*T2*^ but not *Ascl1*^*CreERT2*^ ([Figure 5N--P](#fig5){ref-type="fig"}) suggest that the SVZ regenerates from pre-GEPCOT qNSCs.10.7554/eLife.02669.014Figure 8.Phenotypically and functionally distinct populations of pre-GEPCOT qNSCs and GEPCOT NICs.Glast^high^EGFR^−/low^PlexinB2^mid^CD24^−/low^O4/PSA-NCAM^−/low^Ter119/CD45^−^ pre-GEPCOT cells are a quiescent, TMZ resistant population containing qNSCs that give rise to Glast^mid^EGFR^high^PlexinB2^high^CD24^−/low^O4/PSA-NCAM^−/low^Ter119/CD45^−^ GEPCOT cells that are highly mitotically active in vivo and enriched for NICs. pre-GEPCOT cells include Type B1 cells, GEPCOT cells include Type C cells, and neuroblasts make up Type A SVZ cells ([@bib14]; [@bib13]). Bars for different *Cre* alleles represent the extent of recombination observed after 5 consecutive days of tamoxifen treatment followed by a 2 day chase.**DOI:** [http://dx.doi.org/10.7554/eLife.02669.014](10.7554/eLife.02669.014)

The conclusion that pre-GEPCOT cells include qNSCs is also supported by the sustained contribution of *GFAP-CreER*^*T2*^ marked cells to the SVZ, as *GFAP-CreER*^*T2*^ labeled many pre-GEPCOT cells but few GEPCOT cells or NICs immediately after tamoxifen treatment ([Figure 3A](#fig3){ref-type="fig"}, [Figure 4I](#fig4){ref-type="fig"}). Thus, our data demonstrate that *GFAP-CreER*^*T2*^ recombination is a marker of qNSCs that survive treatment with anti-mitotic agents and contribute to an increasing proportion of pre-GEPCOT cells, GEPCOT cells, and neuroblasts over time ([Figures 4I and 5M--P](#fig4 fig5){ref-type="fig"}).

NSCs are commonly estimated to account for a few percent of cells in germinal zones in the adult mouse brain ([@bib14]; [@bib47]; [@bib58]). Although pre-GEPCOT cells accounted for 6 ± 3% of SVZ cells, this population is likely to be heterogeneous, consistent with its heterogeneous GFAP expression ([Figure 4A](#fig4){ref-type="fig"}). Thus, the actual frequency of qNSCs in the SVZ may be lower than 6%. The current lack of a clonal assay for qNSCs makes it impossible to test the purity of this population. In an effort to identify culture conditions permissive for colony formation by pre-GEPCOT cells we screened 36 different growth factors or medium supplements but none significantly increased colony formation by SVZ cells from normal or TMZ-treated mice ([Supplementary file 1B](#SD1-data){ref-type="supplementary-material"}). Thus, future studies will be required to develop culture conditions that permit efficient colony formation by individual qNSCs and to isolate these cells at high purity.

An interesting question for future studies will be whether there are regional differences in the distributions or properties of pre-GEPCOT qNSCs or GEPCOT NICs within the SVZ, corresponding to regional differences in stem/progenitor cell properties ([@bib45], [@bib44]; [@bib26]).

Germline deficiency for the polycomb family member *Bmi-1* eliminates multipotent NICs and reduces proliferation and neurogenesis in the SVZ ([@bib49]; [@bib7]; [@bib48]; [@bib69]; [@bib6]; [@bib17]). However, the lack of a floxed allele of *Bmi-1*, the death of germline *Bmi-1*-deficient mice before adulthood, and the lack of prospective markers for NSCs made it impossible to directly test whether Bmi-1 was required for the maintenance of adult NSCs in vivo.

Conditional deletion of *Bmi-1* from the fetal and adult SVZ using *Nestin-Cre* ([Figure 6](#fig6){ref-type="fig"}) and *Nestin-CreER*^*T2*^ ([Figure 7](#fig7){ref-type="fig"}) demonstrated that pre-GEPCOT qNSCs and GEPCOT NICs require Bmi-1 to be maintained in normal numbers in the adult forebrain, but the depletion of these cells and the loss of neurogenesis occurred much more gradually than expected. Even when *Bmi-1* was completely deleted in neural stem/progenitor cells during fetal development, normal or near-normal numbers of pre-GEPCOT cells, GEPCOT cells, and SVZ neuroblasts were found in the SVZ of 4 month old *Nestin-Cre*; *Bmi-1*^fl/fl^ mice ([Figure 6L--N](#fig6){ref-type="fig"}). This demonstrates that pre-GEPCOT qNSCs and GEPCOT NICs can persist throughout fetal and postnatal development, and into adulthood, in the absence of *Bmi-1*. This suggests that qNSCs and NICs are less acutely dependent upon *Bmi-1* for their maintenance than expected based on studies of *Bmi-1* germline knockout mice ([@bib67]; [@bib49]; [@bib7]; [@bib48]; [@bib17]).

There are likely several reasons why *Bmi-1* germline knockout mice appeared to exhibit a more severe loss of neural stem/progenitor cells and neurogenesis than is evident in conditional knockout mice. First, the phenotype in *Bmi-1* germline knockout mice may indeed be more severe as non-cell-autonomous effects of *Bmi-1* deficient stroma contribute to stem cell deficits in these mice ([@bib55], [@bib56]). Second, the death of *Bmi-1* germline knockout mice before young adulthood meant that adult phenotypes could not be studied directly and it was assumed that the deficits observed in the early postnatal period would rapidly worsen over time. Third, without the ability to prospectively identify qNSCs or NICs in vivo, these cells could only be studied based on neurosphere formation in culture. Since p16^Ink4a^ and p19^Arf^ expression are induced to a greater extent in culture than in vivo, the severity of *Bmi-1* deficiency phenotypes in the nervous system are sometimes exaggerated in culture ([@bib48]; [@bib22]). Our data indicate that *Bmi-1* is not required for the persistence of NSCs or neurogenesis into adulthood, though both are depleted over time during adulthood after *Bmi-1* deletion.

Consistent with the gradual depletion of pre-GEPCOT cells, GEPCOT cells, and neurogenesis during adulthood after conditional Bmi-1 deletion, we also observed a gradual increase in *Cdkn2a* (*p16*^*Ink4a*^) expression in pre-GEPCOT cells but not in GEPCOT cells ([Figures 6O and 7R](#fig6 fig7){ref-type="fig"}, [Figure 7---figure supplement 2H](#fig7s2){ref-type="fig"}). This suggests that qNSCs are particularly dependent upon Bmi-1 for the repression of *Cdkn2a* (*p16*^*Ink4a*^) expression.

The identification of markers that prospectively identify and isolate distinct populations of qNSCs and NICs will make it possible to characterize their properties in vivo rather than relying upon colony-forming assays in culture. Use of commercially available antibodies against cell surface antigens will enable such studies in a wide range of genetic backgrounds. Our data on Bmi-1 demonstrate how the existence of these markers makes it possible to assess the function of gene products within the neural stem/progenitor cell pool with a more granular appreciation for effects on qNSCs vs NICs.

Materials and methods {#s4}
=====================

Mice {#s4-1}
----

C57Bl/6 were maintained in standard cages with water and standard diet (Teklad 2916) *ad libitum*. *Rosa26*^*CAG-loxp-Stop-loxp-tdTomato(Ai14)*^ (referred to here as *Rosa26-loxp-tdTomato*) ([@bib41]), *Gli1*^*CreERT2*^ ([@bib1]), *Sox2*^*CreERT2*^ ([@bib2]), *Dlx1*^*CreERT2*^ ([@bib65]), *Tg(Slc1a3-CreER*^*T*^*)* ([@bib68]), *Tg(Nestin-Cre)* ([@bib66]) and *Tg(Ubc-GFP)* ([@bib63]) mice were obtained from The Jackson Laboratory (Bar Harbor, ME). *Tg(GFAP-CreER*^*T2*^*)* ([@bib23]) mice were provided by Frank Kirchhoff. *Tg(Nestin-GFP)* ([@bib5]) and *Tg(Nestin-mCherry)* ([@bib12]) mice were kindly provided by Grigori Enikopalov. *Tg(Nestin-CreER*^*T2*^*)* mice were provided by G Fishell ([@bib3]). *Ascl1*^*CreERT2*^ ([@bib31]) mice were housed in the Johnson laboratory. All mice were backcrossed onto a C57BL/Ka background for at least three generations prior to analysis. For BrdU pulses up to 24 hr, 100 mg of BrdU/kg body mass dissolved in PBS was injected i.p. every 6 hours. For 2-week pulses of BrdU, mice were initially injected with 100 mg of BrdU/kg body mass then maintained on drinking water that contained 1 mg/ml BrdU until sacrifice.

Targeting vectors to generate *Bmi1*^*fl*^ mice ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}) were constructed by recombineering ([@bib37]). W4 ES cells were electroporated with the targeting vector and positive clones identified by southern blotting were injected into blastocysts from C57BL/6-Tyr^c-2J^ mice. The resulting male chimeric mice were bred to female C57BL/6-Tyr^c-2J^ mice to obtain germline transmission. The FRT-Neo-FRT cassette was removed by crossing with Flp deleter mice ([@bib62]), and then *Bmi1*^*fl*^ mice were backcrossed onto a C57BL/Ka background for at least 10 generations. Animal protocols were approved by the University of Michigan Committee on the Use and Care of Animals and the UT Southwestern Medical Center Institutional Animal Care and Use Committee (protocol\# 2011-0104).

Induction of recombination using tamoxifen {#s4-2}
------------------------------------------

Tamoxifen (T5648; Sigma, St. Louis, MO) was dissolved in 90% corn oil/10% ethanol at 20 mg/ml, and injected at 80 mg/kg/day i.p. for 5 consecutive days into 8--12 week-old mice, then the mice were chased for 2, 7, 28, or 60 days until analysis. For *Bmi-1* experiments, tamoxifen citrate (Sigma or Spectrum Chemical, New Brunswick, NJ) was given in chow at 400 mg/kg with 5% sucrose (Harlan) to 6 week-old mice for 30 days. Mice were then fed a standard diet for at least 14 days before analysis.

TMZ regeneration assay {#s4-3}
----------------------

TMZ (T2577; Sigma) was dissolved in 25% DMSO/75% 0.9% saline solution at 10 mg/ml by heating briefly to 90--100°C, then shaking and rapidly cooling. Mice were injected at 100 mg/kg/day for 3 consecutive days then allowed to recover for 3--90 days before analysis. Mice with enlarged spleen or thymus (sometimes present at 90 days after TMZ treatment) were excluded from analysis.

SVZ cell preparation {#s4-4}
--------------------

SVZs from adult (8--60 week old) mice were dissected as described ([@bib46]). SVZs were minced and digested with 300 µl of trypsin solution (Ca and Mg-free HBSS, 10 mM HEPES, 0.5 mM EDTA, 0.25 mg/ml trypsin (EMD Millipore, Billerica, MA), 10 μg/ml DNase I (Roche, Basel, Switzerland), pH 7.6) at 37°C for 20 min. Digestion was quenched with three volumes of staining medium (440 ml Leibovitz L-15 medium, 50 ml water, 5 ml 1M HEPES pH 7.3--7.4, 5 ml 100x Pen-Strep, 20 ml 77.7 mM EDTA pH 8.0 \[prepared from Na~2~H~2~EDTA\], 1 g bovine serum albumin \[A7030; Sigma\]) containing 100 μg/ml trypsin inhibitor (T6522; Sigma) and 10 μg/ml DNase I (Roche).

Digested SVZ pieces were centrifuged (220×*g*, 4 min, 4°C) then fresh staining medium was added and the pieces were triturated in 300 μl by gently drawing into a P1000 pipetman and expelling 25 times without forming bubbles. The cell suspension was then filtered through a 45-micron mesh, counted on a hemocytometer, and added to culture or processed for flow cytometry. Neurosphere formation, self-renewal, and differentiation assays were performed as described previously ([@bib49]; [@bib54]), except that in some cases 10 μM Y-27632 hydrochloride (Rho-associated protein kinase inhibitor; Tocris Biosciences 1254, Bristol, UK) and 20 ng/ml IGF-1 (291-G1; R&D Systems, Minneapolis, MN) were also added to the culture medium because they were found to promote clonogenesis after sorting adult SVZ cells (data not shown). For adherent colony formation, *Tg(Ubc-GFP)* SVZ cells were co-cultured with ∼80--90% confluent nontransgenic neonatal SVZ-derived astrocytes isolated and passaged twice prior to the experiment. GFP fluorescence was used to assess colony formation after 12--20 days in culture.

Flow cytometry and sorting {#s4-5}
--------------------------

For screening for markers of NICs, typically SVZs from 5--10 mice were pooled and stained with antibodies then analyzed using a 4 laser FACSAria III (Becton Dickenson, Franklin Lakes, NJ). Markers that stained SVZ cells heterogeneously were used to separate SVZ cells by flow cytometry into different fractions then sorted into non-adherent cultures to measure the frequency of NICs.

To stain SVZ cells with the combination of markers used to isolate GEPCOT or pre-GEPCOT cells, dissociated SVZ cells were centrifuged (220×*g*, 4 min, 4°C) and resuspended in 100 μl staining medium per brain. Then the following antibodies were added: BV421 anti-Ter119 (116233; 1/100; Biolegend, San Diego, CA), BV421 anti-CD45 (103133; 1/100; Biolegend), APC-eFluor 780 anti-CD24 (47-0242-82; 1/200; eBioscience, San Diego, CA), 5A5 ascites (anti-PSA-NCAM; Developmental Studies Hybridoma Bank, Iowa City, IA, 1/100), O4 ascites (1/200), anti-PlexinB2 (14-5665-82; 1/100; eBioscience), biotinylated anti-EGFR (BAF1280, 1/200; R&D Systems), anti-Glast (130-095-822; 1/10; Miltenyi Biotec, Bergisch Gladbach, Germany), and DAPI (50 μg/ml, 1/100). After adding antibodies, the cells were incubated on ice for 45 min, then washed with 2.5 ml fresh staining medium and pelleted (220g for 4 min at 4°C) and resuspended in secondary antibodies. Typically we used the following combination: APC anti-mouse IgG2a (115-135-206; 1/200; Jackson Immunoresearch, West Grove, PA), PE anti-hamster IgG (127-115-160; 1/200; Jackson Immunoresearch), PE-Cy7 anti-mouse IgM (25-5790-82; 1/100; eBioscience), BV605-Streptavidin (563260; 1/200; BD Biosciences). However when analyzing mice expressing tdTomato we used the following alternative secondary antibodies: PerCP-eFluor 710 anti-mouse IgG (46-4010-82; 1/100; eBioscience), APC anti-hamster IgG (127-135-160; 1/200; Jackson Immunoresearch), PE-Cy7 anti-mouse IgM (25-5790-82; 1/100; eBioscience), BV605-Streptavidin (563260; 1/200; BD Biosciences). Cells were stained with secondary antibodies on ice for 45 min, then washed and pelleted as above, and analyzed on the FACSAria in a volume of 200 μl per brain.

When sorting cells onto slides, a drop of 8 μl staining medium was placed on a SuperFrost Plus slide, and 100--300 cells were sorted directly into the drop. The slide was then kept humid for 45--60 min at ambient temperature to allow the cells to attach to the glass, then the cells were fixed with 4% PFA (20 min, RT). Cells were then permeabilized and stained with rat anti-BrdU (Abcam, Cambridge, MA, clone Bu1/75, 1/500, after heat-mediated antigen retrieval), mouse anti-Nestin (BD clone Rat-401, 1/100 after heat-mediated antigen retrieval), and rabbit anti-GFAP (Dako, Carpinteria, CA, 1/3000) antibodies using standard techniques.

Immunostaining {#s4-6}
--------------

Brains were fixed overnight at 4°C in 4% PFA in PBS, then cryoprotected in 30% sucrose in PBS for 1--3 days at 4°C, then frozen in OCT or cryogel on dry ice after 3--12 hr equilibration at 4°C. Sections were cut at 12 μm thickness spanning the rostral half of the SVZ (typically 6 sections per slide) or the entire olfactory bulb (typically 8 sections per slide). Sections were immunostained with the following primary antibodies: rat anti-BrdU (Abcam clone Bu1/75, 1/500, after heat-mediated antigen retrieval), guinea pig anti-Dcx (1/1000; Millipore), mouse anti-Mcm2 (BD Biosciences, 1/500, after heat-mediated antigen retrieval), rat anti-Ki67 (1/500; eBioscience), mouse anti-tyrosine hydroxylase (1/1000; Millipore), rabbit anti-calretinin (1/1000; Sigma), rabbit anti-calbindin (1/500; Millipore), rabbit anti-S100β (1/1000; Dako), rabbit anti-GST-pi (1/3000; Enzo, Farmingdale, NY), and mouse anti-NeuN (1/1000; Millipore). Fixed whole-mount SVZs were stained with mouse anti-acetylated tubulin (1/1000; Sigma), rabbit anti-β-catenin (1/500; Sigma), mouse anti-GFAP (1/3000; Sigma), and goat anti-EGFR (1/250; R&D Systems). Alexa Fluor 488-, 555-, and 647-conjugated secondary antibodies were used (Life Technologies, Carlsbad, CA).

Western blotting {#s4-7}
----------------

Cells were resuspended in 10% trichloracetic acid (TCA, Sigma). Extracts were incubated on ice for at least 15 min and centrifuged at 16,100×*g* at 4°C for 15 min. Precipitates were washed in acetone twice and dried. The pellets were solubilized in 9M urea, 2% Triton X-100, and 1% DTT. LDS loading buffer (Invitrogen) was added and the pellet was heated at 70°C for 10 min. Samples were separated on Bis-Trispolyacrylamide gels (Invitrogen) and transferred to PVDF membrane (Millipore or BioRad, Hercules, CA). Membranes were treated with the SuperSignal Western Blot Enhancer (Thermo Scientific, Waltham, MA) and blots were developed with the SuperSignal West Femto chemiluminescence kit (Thermo Scientific). Blots were stripped with 1% SDS, 25 mM glycine (pH 2) prior to reprobing. The following primary antibodies were used for western blots: β-Actin (AC-15; Santa Cruz Biotechnology, Santa Cruz, CA), Bmi-1 (F6; Millipore).

Quantitative PCR {#s4-8}
----------------

Cells were sorted directly into RLT plus buffer (Qiagen, Venlo, Netherlands) supplemented with 2-mercaptoethanol. RNA was extracted with the RNeasy micro plus kit (Qiagen) and cDNA was synthesized with the RT^2^ First Strand Kit (Qiagen). Reactions were run in 20 μl volumes with SYBR green and a LightCycler 480 (Roche Applied Science). Primer sequences were: *Bmi-1* F ([Figures 6A](#fig6){ref-type="fig"}), 5′-CCAATGGCTCCAATGAAGACC-3′, *Bmi-1* R ([Figures 6A](#fig6){ref-type="fig"}), 5′-TTGCTGCTGGGCATCGTAAG-3′, *Bmi-1* F ([Figure 6---figure supplement 1G](#fig6s1){ref-type="fig"}), 5′-CGCTCTTTCCGGGATCTTT-3′, *Bmi-1* R ([Figure 6---figure supplement 1G](#fig6s1){ref-type="fig"}), 5′-CTCCACACAGGACACACATTA-3′, *Cdkn2a* (*p16*^*Ink4a*^) F, 5′-GTGTGCATGACGTGCGGG-3′, *Cdkn2a* (*p16*^*Ink4a*^) R, 5′-GCAGTTCGAATCTGCACCGTAG-3′; *β-actin* F, 5′-CGTCGACAACGGCTCCGGCATG-3′; *β-actin* R, 5′-GGGCCTCGTCACCCACATAGGAG-3′; *Nestin* F 5′-GGGCCCAGAGCTTTCCCACG-3′; *Nestin* R 5′-GGGCATGCACCAGACCCTGTG-3′.

Technical considerations when sorting adult SVZ cells for neurosphere assays {#s4-9}
----------------------------------------------------------------------------

Neurosphere assays were done as previously published by our lab ([@bib49], [@bib48]; [@bib54]). However when sorting adult SVZ cells for neurosphere assays several important technical points require attention:

### Debris elimination {#s4-9-1}

The extensive debris in adult SVZ cell preps complicates the determination of which events are real cells. This is not a problem for embryonic or neonatal cell preparations. We compared multiple strategies to eliminate debris from adult SVZ preparations. The simplest, least expensive, and most reproducible solution was stringent forward scatter and side scatter gating as shown in [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}. To use this technique it is important to calibrate the forward scatter and side scatter voltages using freshly isolated bone marrow cells because even a small change in PMT voltages can dramatically affect cell yield and the amount of debris contaminating the cellular fraction. Before every experiment we aligned the myeloid population into the center of the forward scatter/side scatter plot \[FSC-Area = 125k, SSC-Area = 125k\] then we ensured that the forward scatter threshold was set as high as possible without eliminating cells (typically 75000 and did not require daily adjustment). When the forward scatter and side scatter voltages are properly calibrated there should be a prominent population of adult SVZ cells with similar FSC/SSC as lymphoid cells.

There are drawbacks to stringent forward scatter and side scatter gating. Some debris has similar FSC/SSC characteristics as live SVZ cells (typically ∼10% of events in the live SVZ scatter fraction represent debris as judged by DAPI staining after sorting on slides), and some cells are lost in the debris exclusion gate including a few cells with neurosphere-forming activity (generally ∼25% of NICs are excluded by the debris exclusion gate) and all ependymal cells (which have very high side scatter properties due to their cilia). As a result we also explored other options to increase cell purity and yield which we will summarize here.

We tried two other techniques to eliminate debris: sucrose gradient and myelin depletion. For sucrose gradient, we resuspended pelleted SVZ cells in 10 ml of 0.9M sucrose in staining medium, then centrifuged the cells (750×*g*, 10 min, 4°C) and decanted the supernatant. The sucrose gradient typically eliminated ∼90% of debris but also lost ∼50% of cells. We performed myelin depletion using the Myelin Removal Beads II kit (130-096-733; Miltenyi Biotec) according to the manufacturer\'s instructions. Myelin depletion typically eliminated ∼95--98% of debris but also eliminated ∼50% of cells. Because of the unacceptable losses in cell yields, for routine experiments we did not eliminate debris using either of these methods. However when cell purity is paramount these debris elimination techniques may be useful.

We also attempted other techniques to enrich for cells and to deplete debris using vital dyes. We tried Calcein AM (C3099; Life Technologies) and CFSE (C1157; Life Technologies) but these stains did not distinguish adequately between cells and debris. We also tried Hoechst 33342 (H1399; Life Technologies) and Vybrant DyeCycle Violet (V35003; Life Technologies), and although these stains did distinguish between cells and debris we found that these reagents were not useful because (1) the intensity of staining varied substantially across days, (2) staining of other markers (in particular Glast) was negatively affected by using these reagents, and (3) efficiency of clonogenesis after sorting was negatively impacted by using either of these reagents. As a result we did not use these dyes for routine experiments, but they could be useful when cell yield is paramount.

Finally we also used the fluorescent transgenic lines *Nestin-GFP* and *Nestin-mCherry* ([@bib5]; [@bib12]). These lines allowed easy discrimination of SVZ cells from debris because of their bright, unambiguous expression in cells. Using *Nestin-GFP* or *Nestin-mCherry* and gating on GFP^+^DAPI^−^ (or mCherry^+^DAPI^−^) events typically gave ∼50% greater cell yield and greater cell purity than when only using scatter-gating for cell identification. This is presumably because some Nestin-GFP+ or Nestin-Cherry+ cells (such as ependymal cells) appear as debris by FSC/SSC profile and would otherwise be excluded. However we did not wish to use transgenic lines to purify GEPCOT or pre-GEPCOT cells as this would limit the technique to these genetic backgrounds, and because express these transgenes are not uniformly expressed by pre-GEPCOT cells. However, for certain applications where high cell purity and yield are both paramount, or ependymal cells are desired, then *Nestin-GFP* or *Nestin-mCherry* may be useful.

### EDTA in staining medium increased GEPCOT cell yield {#s4-9-2}

In our experiments the staining medium we employed contained 3.0 mM EDTA, enough to neutralize 2.7 mM of divalent cations in the staining medium (with a small surplus). We found that this slight excess of EDTA had a large effect (2--3-fold) on the yield of GEPCOT cells, probably by preventing clumping of GEPCOT cells with debris and/or other cells. The EDTA also prevented clogging of the nozzle during sorting. EDTA was found to be better than EGTA for this purpose. However it was important to maintain the osmolarity of the staining medium when adding EDTA or clonogenesis was negatively impacted. We pre-diluted 0.5M EDTA (made from Na~2~H~2~EDTA, pH 8.0) to 77.7 mM (309 mOsm) before adding it to the staining medium.

### Growth medium pH must be kept neutral during sorting by preventing equilibration with the atmosphere {#s4-9-3}

When sorting cells directly into culture medium it is essential to keep the pH of the medium constant. The phenol red indicator should maintain a red-orange color (pH 7.2--7.4) before, during, and after the sort. Typically we keep each plate in a Ziploc bag filled with 6% CO~2~/93% N~2~/1% O~2~ prior to the sort, then sort one plate in 2--3 min or less, and return it to a freshly gassed Ziploc bag until transferring the plate to a humidified 37°C, CO~2~ incubator for culture. By keeping plates in 6% CO~2~ before and after the sort, the culture medium does not equilibrate with the air (which would deplete CO~2~ from the medium and increase pH to levels incompatible with cell survival).

### Rock inhibitor (Y-27632) and IGF1 increase clonogenesis after sorting {#s4-9-4}

The process of being sorted has a negative effect on neurosphere formation from adult SVZ cells: at the beginning of our experiments we observed a ∼threefold loss of activity in sorted live SVZ cells compared to crude unsorted cells. Sorted neonatal SVZ cells do not show this problem. We wondered how to sort gently to overcome the fragility of adult SVZ cells.

Addition of the ROCK inhibitor, Y-27632 hydrochloride, to the culture medium after sorting (10 μM) increased neurosphere formation by adult cells approximately twofold after sorting but did not have any effect on adult SVZ cells pipetted into the culture medium, on sorted neonatal SVZ cells, or on crude neonatal SVZ cells. We also found that IGF1 (20 ng/ml) further improved clonogenesis after sorting. The mechanisms underlying these effects are unclear but may involve promotion of cell survival after sorting or repression of BMP signaling ([@bib24]). When using both these culture additives, there was little difference between sorted live SVZ cells and an equal number of cells added to culture by pipette in terms of the numbers of neurospheres they made.

### Preventing neurosphere aggregation after sorting {#s4-9-5}

Neurospheres can aggregate and fuse in culture, particularly when cultured at higher densities or when plates are moved (facilitating collisions among neurospheres) during the culture period ([@bib64]). To minimize this problem we took several precautions. First, we always sorted cells into culture at clonal (low) density: 1000 cells in 1.5 ml medium (0.66 cells/μl) in each well of a 6 well-plate. Second, we maintained a separate incubator specifically for neurosphere cultures that was only opened sparingly to prevent mechanical disturbances or changes in CO~2~ concentrations.

Finally, we found that chick embryonic extract (CEE) ([@bib49]) can prevent cell fusion after sorting. In the absence of CEE, sorted cell-derived primary neurospheres were few in number and very large, suggesting extensive sphere fusion. After adding 10% CEE to the culture medium, sorted cell-derived primary neurospheres were indistinguishable in size and number from neurospheres cultured from cells pipetted into culture. We found that the combination of 10% CEE plus 10 μM Y-27632 hydrochloride plus 20 ng/ml IGF1 maximized the formation of non-aggregating neurospheres from sorted adult SVZ cells.
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eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see [review process](http://elifesciences.org/review-process)). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.

Thank you for sending your work entitled "Prospective identification of functionally distinct neural stem cells and neurosphere-initiating cells in the forebrain" for consideration at *eLife*. Your article has been favorably evaluated by Janet Rossant (Senior editor) and 3 reviewers, one of whom is a member of our Board of Reviewing Editors.

The Reviewing editor and the other reviewers discussed their comments before we reached this decision, and the Reviewing editor has assembled the following comments to help you prepare a revised submission.

The general consensus of the reviewers was that the data are extensive, of high quality, use cutting edge approaches, and support the conclusions. In addition, the findings make a significant contribution to the field of adult neural stem cells, particularly with regard to the ongoing search for the "true" quiescent adult neural stem cell. However, the reviewers did raise a number of issues that, if addressed, would strengthen the manuscript, as follows:

1\) The authors indicate that they could not grow colonies from the pre-GEPCOT cells under neurosphere conditions or under adherent conditions. Nonetheless, it is clear that these cells must proliferate under some conditions, since they repopulate the GEPCOT compartment following its ablation. Any data addressing potential growth factor requirements for these cells would greatly enhance the manuscript. If the authors have tried to identify such growth factors and have been unsuccessful then even that negative data would be informative.

2\) Given the link between p16 and senescence, have the authors ever asked whether senescence is the relevant mechanism for depletion of neural stem cells in their various Bmi1 mouse models?

3\) In [Figure 6B](#fig6){ref-type="fig"}, there are many non-specific bands, and it is not clear whether Bmi-1 protein expression was lost in the mutant mice. The authors should improve the data, or alternatively perform qPCR to confirm the loss of Bmi-1 expression.

On a more minor note:

1\) One of the surprising findings of this manuscript is the relatively high frequency of the pre-GEPCOT cells (6%). It is generally assumed in the field that the quiescent neural stem cells should be a rare population. The authors do indicate in the discussion that the pre-GEPCOT cells they are sorting are likely to be heterogeneous. However, it would be worth discussing this issue further.

2\) It would be nice to see the enhanced GFAP staining that the authors allude to when they describe the floxed *Bmi1*;*Nestin-Cre* mice in [Figure 6](#fig6){ref-type="fig"}.

3\) The proportions of new astrocytes and oligodendrocytes that are made from their BrdU-positive proliferating SVZ cells in vivo seem to be very small. It would help the reader if the authors were to compare the relative proportions of BrdU-positive cells that made neurons versus glia over the relevant timeframes.

10.7554/eLife.02669.017

Author response

Before getting into the reviewer comments I would like to note that in addition to the new data we have provided to address reviewer comments, we have also added other new data to strengthen the manuscript:

We have added new data extending the *GFAP-CreER*^*T2*^ lineage tracing to 35 days during regeneration after temozolomide (TMZ) treatment ([Figure 5P](#fig5){ref-type="fig"}). In the original manuscript we had chased for only 22 days. This longer chase period strengthens the evidence that the cells that are responsible for the regeneration of GECPOT neurosphere-initiating cells (NICs) and other SVZ cells after TMZ ablation are GFAP^+^. Since GFAP is one of the most specific markers of pre-GEPCOT cells, this further supports our conclusion that quiescent pre-GEPCOT cells are the stem cells of the SVZ.

We have also added new data on neurogenesis in *Nestin-Cre; Bmi-1*^*fl/fl*^ mice. In the original manuscript we showed that *Bmi-1* deletion significantly reduced neurogenesis in 14-month-old *Nestin-Cre; Bmi-1*^*fl/fl*^ mice relative to littermate controls. In the revised manuscript we have expanded our analysis to include neurogenesis in 4-month-old *Nestin-Cre; Bmi-1*^*fl/fl*^ mice, showing that neurogenesis is normal in these mice (see [Figure 6H](#fig6){ref-type="fig"}). This further demonstrates that even when *Bmi-1* is deleted throughout the nervous system during fetal development, stem cells and neurogenesis persist into young adulthood and are not depleted until around a year of age. Bmi-1 is therefore not absolutely required for the maintenance of adult neural stem cells, in contrast to what has been widely assumed based on studies of germline knockout mice.

Review comments:

*1) The authors indicate that they could not grow colonies from the pre-GEPCOT cells under neurosphere conditions or under adherent conditions. Nonetheless, it is clear that these cells must proliferate under some conditions, since they repopulate the GEPCOT compartment following its ablation. Any data addressing potential growth factor requirements for these cells would greatly enhance the manuscript. If the authors have tried to identify such growth factors and have been unsuccessful then even that negative data would be informative*.

We agree that it should, in principle, be possible to identify culture conditions that enable colony-formation by pre-GEPCOT cells and have worked very hard to do this. To date, we have tested the effects of 36 different growth factors or medium supplements on adherent or non-adherent colony formation by SVZ cells from normal or TMZ-treated mice. Since TMZ treatment ablates GEPCOT NICs, any growth factor that enables colony formation by pre-GEPCOT cells should profoundly increase colony formation by SVZ cells from TMZ-treated mice. Out of the 36 growth factors and medium supplements we have tested so far, 5 significantly reduced colony-formation but none significantly increased colony formation. The new data have been added to Supplementary File 1B. We will continue testing additional growth factors and medium supplements in future studies.

*2) Given the link between p16 and senescence, have the authors ever asked whether senescence is the relevant mechanism for depletion of neural stem* *cells in their various Bmi1 mouse models?*

We have added new data further exploring *p16*^*Ink4a*^ expression after *Bmi-1* deletion. In the original manuscript we demonstrated in *Nestin-Cre; Bmi-1*^*fl/fl*^ mice that *p16*^*Ink4a*^ expression increased after *Bmi-1* deletion in pre-GEPCOT but not GEPCOT cells (see [Figure 6O](#fig6){ref-type="fig"}). In the revised manuscript, we have added new data demonstrating in *Nestin-CreER*^*T2*^*; Bmi-1*^*fl/fl*^ mice that *p16*^*Ink4a*^ expression also increased in pre-GEPCOT but not GEPCOT cells (see [Figure 7R](#fig7){ref-type="fig"}). These results demonstrate that quiescent neural stem cells are particularly dependent upon Bmi-1 for the repression of *p16*^*Ink4a*^ expression, providing a molecular distinction in the way in which Bmi-1 functions in pre-GEPCOT versus GEPCOT cells.

The most commonly used marker of cellular senescence is β-galactosidase staining. We have attempted to test whether *Bmi-1* deletion induced cellular senescence by staining for senescence-associated β-galactosidase activity. However, relative to control cells, we have not been able to detect any increase in senescence-associated β-galactosidase activity in pre-GEPCOT cells from 14-month-old *Nestin-Cre; Bmi-1*^*fl/fl*^ mice or in cultured neural stem/progenitor cells from *Bmi-1* germline knockout mice. We have added this information to the text of the revised manuscript; however, we cannot entirely exclude the possibility of senescence among *Bmi-1* deficient neural stem cells as there are no definitive markers of cellular senescence in vivo.

We are also attempting to test whether *p16*^*Ink4a*^ deficiency rescues the depletion of pre-GEPCOT and GEPCOT cells after *Bmi-1* deletion but have not yet been able to generate definitive results for technical reasons. We initially attempted to test this by generating *Nestin-CreER*^*T2*^*; Bmi1*^*fl/fl*^*; p16*^*Ink4a*^*-p19*^*Arf\ -/-*^ compound mutant mice. However, germline deletion of *p16*^*Ink4a*^*-p19*^*Arf*^ leads to the death of mice from hematopoietic malignancies by around 5 months of age. Therefore, these mice died before we could test whether there was a rescue of neural stem cell function. We have more recently generated *Nestin-CreER*^*T2*^*; Bmi1*^*fl/fl*^*; p16*^*Ink4a\ fl/fl*^ mice but will have to age these mice for at least a year to test whether conditional *p16*^*Ink4a*^ deletion rescues the depletion of *Bmi-1* deficient pre-GEPCOT and GEPCOT cells (see [Figure 7P](#fig7){ref-type="fig"}).

*3) In* [*Figure 6B*](#fig6){ref-type="fig"}*, there are many non-specific bands, and it is not clear whether Bmi-1 protein expression was lost in the mutant mice. The authors should improve the data, or alternatively perform qPCR to confirm the loss of Bmi-1 expression*.

We have redone the western blot in [Figure 6B](#fig6){ref-type="fig"} and have replaced the blot shown in the original manuscript with another blot that is cleaner and includes more controls. Consistent with our conclusions in the original manuscript, the new blot shows that conditional deletion of *Bmi-1* using *Nestin-Cre* leads to a complete or near complete, loss of Bmi-1 protein throughout the cortex and SVZ (see new [Figure 6B](#fig6){ref-type="fig"}). We have also included new RT-PCR data demonstrating that SVZ cells, GEPCOT cells, and pre-GEPCOT cells from *Nestin-Cre; Bmi-1*^*fl/fl*^ mice generally lack detectable *Bmi-1* mRNA, in contrast to littermate controls (see new [Figure 6-figure supplement 1G](#fig6s1){ref-type="fig"}). These new data supplement the genomic DNA PCR data in the original manuscript showing that SVZ cells, GEPCOT cells, and pre-GEPCOT cells from *Nestin-Cre; Bmi-1*^*fl/fl*^ mice all exhibit complete *Bmi-1* recombination (see [Figure 6F](#fig6){ref-type="fig"}). Thus, PCR analysis of genomic DNA, RT-PCR analysis of mRNA, and western analysis of protein all indicate efficient deletion of *Bmi-1* from SVZ cells, GEPCOT cells, and pre-GEPCOT cells.

*On a more* *minor note:*

*1) One of the surprising findings of this manuscript is the relatively high frequency of the pre-GEPCOT cells (6%). It is generally assumed in the field that the quiescent neural stem cells should be a rare population. The authors do indicate in the discussion that the pre-GEPCOT cells they are sorting are likely to be heterogeneous. However, it would be worth discussing this issue further*.

We have added new text to discuss this issue. There are two important points. First, the pre-GEPCOT cell population is probably not pure. However, given the lack of a clonal assay to detect quiescent neural stem cells we have no way to test purity. This means that to exclude non-stem cells from this population we will have to perform fate mapping with each potential non-stem cell marker. This will take a long time. Second, we should not expect quiescent neural stem cells to be rare. The idea that quiescent stem cells should be rare comes from the hematopoietic system, where stem cells are always rare and are always fated to form massive numbers of progeny. The nervous system has adopted a fundamentally different strategy in which stem cells (when they are present) are common, but are each fated to form relatively small numbers of progeny in vivo. Fate mapping of neural stem cells in multiple regions of the developing and adult nervous system has shown that undifferentiated neural stem cells undergo only a small number of divisions before terminally differentiating (e.g. PNAS 110: E1045; Cell Stem Cell 8: 566; Cell 145: 1142). Neural stem cells are commonly estimated to account for a few percent of the cells in germinal zones of the adult nervous system (e.g., Cell Stem Cell 11: 265; PNAS 106: 6387; J. Neurosci. 17: 5046).

*2) It would be nice to see the enhanced GFAP staining that the authors allude to when they describe the floxed* Bmi1;Nestin-Cre *mice in* [*Figure 6*](#fig6){ref-type="fig"}.

We have added a new figure showing the dramatic increase in GFAP staining in the forebrain of young adult *Nestin-Cre; Bmi-1*^*fl/fl*^ mice (see [Figure 6-figure supplement 1F](#fig6s1){ref-type="fig"}). This effect was not observed in young adult *Nestin-CreER*^*T2*^*; Bmi-1*^*fl/fl*^ mice. This appears to be a developmental consequence of *Bmi-1* deficiency in neural stem/progenitor cells or in glia.

*3) The proportions of new astrocytes and oligodendrocytes that are made from their BrdU-positive proliferating SVZ cells in vivo seem to be very small. It would help the reader if the authors were to compare the relative proportions of BrdU-positive cells that made neurons versus glia over the relevant timeframes*.

We have revised the text to make clear that the vast majority of newborn cells that arise in the adult olfactory bulb are neurons, such that the proportion of new astrocytes and oligodendrocytes in our experiments was very small. This is consistent with a number of prior studies. Lineage tracing by multiple techniques (Cre/Lox, retrovirus, and BrdU) indicates that olfactory bulb neurons make up the vast majority of SVZ-derived mature cells in the mouse brain (e.g., Science 317: 381; J. Neurosci. 27: 12623; Nature 443: 448). Newborn mature glia are generated, but on a much smaller scale (e.g., J. Neurosci. 26: 7907; Genesis 47: 122).

[^1]: These authors contributed equally to this work.
